Disease on EC 1.14.99.1 - prostaglandin-endoperoxide synthase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
11beta-hydroxysteroid dehydrogenase deficiency
Interactions between 11beta-hydroxysteroid dehydrogenase and COX-2 in kidney.
Aberrant Crypt Foci
15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis.
A 116-kDa phytoglycoprotein inhibits aberrant crypt foci formation through modulation of manganese superoxide dismutase, inducible nitric oxide synthase, cyclooxygenase-2, nuclear factor-kappa B, activator protein-1, and proliferating cell nuclear antigen in 1,2-dimethylhydrazine/dextran sodium sulfate-treated ICR mice.
A high-fat diet generates alterations in nuclear receptor expression: prevention by vitamin A and links with cyclooxygenase-2 and beta-catenin.
Anthocyanin-rich extracts inhibit multiple biomarkers of colon cancer in rats.
Anti-inflammatory and proapoptotic effects of umbelliferone in colon carcinogenesis.
Apigenin and naringenin suppress colon carcinogenesis through the aberrant crypt stage in azoxymethane-treated rats.
Aspirin, but not sodium salicylate, indomethacin, or nabumetone, reversibly suppresses 1,2-dimethylhydrazine-induced colonic aberrant crypt foci in rats.
Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis.
Chemopreventive effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on 1, 2-dimethylhydrazine-induced rat colon carcinogenesis.
Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer.
Chemopreventive potential of diallylsulfide, lycopene and theaflavin during chemically induced colon carcinogenesis in rat colon through modulation of cyclooxygenase-2 and inducible nitric oxide synthase pathways.
Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Coenzyme Q10 attenuated DMH-induced precancerous lesions in SD rats.
COX-2 and iNOS, good targets for chemoprevention of colon cancer.
Cyclooxygenase-2 and Hypoxia-Inducible Factor-1alpha protein expression is related to inflammation, and up-regulated since the early steps of colorectal carcinogenesis.
Cyclooxygenase-2 is overexpressed in aberrant crypt foci of smokers.
Dietary cardamom inhibits the formation of azoxymethane-induced aberrant crypt foci in mice and reduces COX-2 and iNOS expression in the colon.
Dose-response assessment of the anti-cancer efficacy of soy isoflavones in dimethylhydrazine-treated rats fed 6% fructooligosaccharide.
Energy restriction reduces the number of advanced aberrant crypt foci and attenuates the expression of colonic transforming growth factor beta and cyclooxygenase isoforms in Zucker obese (fa/fa) rats.
Enhanced chemopreventive effects of a hydrogen sulfide-releasing anti-inflammatory drug (ATB-346) in experimental colorectal cancer.
Evaluation of a selective prostaglandin E receptor EP1 antagonist for potential properties in colon carcinogenesis.
Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis.
Fluoxetine induces preventive and complex effects against colon cancer development in epithelial and stromal areas in rats.
Fructooligosaccharide and soy isoflavone suppress colonic aberrant crypt foci and cyclooxygenase-2 expression in dimethylhydrazine-treated rats.
Fructooligosaccharide associated with celecoxib reduces the number of aberrant crypt foci in the colon of rats.
Germinated brown rice (GBR) reduces the incidence of aberrant crypt foci with the involvement of beta-catenin and COX-2 in azoxymethane-induced colon cancer in rats.
Glutathione-S-transferase P1-1 protects aberrant crypt foci from apoptosis induced by deoxycholic acid.
Indian food ingredients and cancer prevention - an experimental evaluation of anticarcinogenic effects of garlic in rat colon.
Inhibition of azoxymethane-induced aberrant crypt foci in rat by diphenylmethyl selenocyanate through downregulation of COX-2 and modulation of glutathione-S-transferase and lipid peroxidation.
Inhibitory effect of NS-398, a selective cyclooxygenase-2 inhibitor, on azoxymethane-induced aberrant crypt foci in colon carcinogenesis of F344 rats.
Inhibitory effects of etodolac, a selective COX-2 inhibitor, on the occurrence of tumors in colitis-induced tumorigenesis model in rats.
Is COX-2 a 'collateral' target in cancer prevention?
JTE-522, a selective cyclooxygenase-2 inhibitor, inhibits induction but not growth and invasion of 1,2-dimethylhydrazine-induced tubular adenocarcinomas of colon in rats.
Light and Moderate Doses of Ethanol in Chemical Carcinogenesis of the Colon in Rats.
Modulation of experimental colon tumorigenesis by types and amounts of dietary fatty acids.
Molecular changes in the early stage of colon carcinogenesis in rats treated with azoxymethane.
Non-steroidal anti-inflammatory drugs with different cyclooxygenase inhibitory profiles that prevent aberrant crypt foci formation but vary in acute gastrotoxicity in a rat model.
Predisposition to colorectal cancer in rats with resolved colitis: role of cyclooxygenase-2-derived prostaglandin d2.
Soy Saponins Meditate the Progression of Colon Cancer in Rats by Inhibiting the Activity of ? -Glucuronidase and the Number of Aberrant Crypt Foci but Not Cyclooxygenase-2 Activity.
Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclooxygenase 2.
Suppression of azoxymethane-induced colon cancer development in rats by a cyclooxygenase-1 selective inhibitor, mofezolac.
Suppression of colonic aberrant crypt foci by soy isoflavones is dose-independent in dimethylhydrazine-treated rats.
Suppressive effect of the herbal medicine Oren-gedoku-to on cyclooxygenase-2 activity and azoxymethane-induced aberrant crypt foci development in rats.
Vitamin E supplementation in chemical colorectal carcinogenesis: a two-edged knife.
[Effects of combined use of curcumin and catechin on cyclooxygenase-2 mRNA expression in dimethylhydrazine-induced rat colon carcinogenesis]
Abortion, Habitual
Fragile X-related protein 1 (FXR1) regulates cyclooxygenase-2 (COX-2) expression at the maternal?fetal interface.
Relationship between expression of COX-2, TNF-?, IL-6 and autoimmune-type recurrent miscarriage.
Abortion, Spontaneous
Hormonal Regulation of Physiology, Innate Immunity and Antibody Response to H1N1 Influenza Virus Infection During Pregnancy.
Proinflammatory cytokines induced altered expression of cyclooxygenase-2 gene results in unreceptive endometrium in women with idiopathic recurrent spontaneous miscarriage.
Prostaglandins in the fetal circulation following maternal ingestion of a prostaglandin synthetase inhibitor during mid-pregnancy.
Relationship between expression of COX-2, TNF-?, IL-6 and autoimmune-type recurrent miscarriage.
Role of cyclooxygenase-2 signaling pathway dysfunction in unexplained recurrent spontaneous abortion.
[Developmental toxicity of the over-the-counter analgetics and antypiretics].
Abscess
Contribution of the prostaglandin E2/EP2 receptor-signaling pathway in abscess formation in rat zymosan-induced pleurisy.
Acidosis
Acidic environment activates inflammatory programs in fibroblasts via a cAMP-MAPK pathway.
Acidosis differently modulates the inflammatory program in monocytes and macrophages.
Cardiopulmonary effects of tumor necrosis factor-alpha in the piglet: influence of cyclooxygenase inhibition.
Enhancement of hypoxic pulmonary vasoconstriction by metabolic acidosis in dogs.
HIGH-TIDAL VOLUME VENTILATION AGGRAVATES SEPSIS-INDUCED MULTIORGAN DYSFUNCTION IN A DEXAMETHASONE-INHIBITABLE MANNER.
Hyperkalemia induced by indomethacin and naproxen and reversed by fludrocortisone.
Indomethacin abolishes cerebral blood flow increase in response to acetazolamide-induced extracellular acidosis: a mechanism for its effect on hypercapnia?
Inhibition by free radical scavengers and by cyclooxygenase inhibitors of the effect of acidosis on calcium transport by masseter muscle sarcoplasmic reticulum.
Prolonged hypercapnia-evoked cerebral hyperemia via K(+) channel- and prostaglandin E(2)-dependent endothelial nitric oxide synthase induction.
Regulation of COX-2 mediates acid-induced bone calcium efflux in vitro.
Acidosis, Lactic
A reexamination of the role of oxygen in retrolental fibroplasia.
Effect of calpain inhibitor I, an inhibitor of the proteolysis of I kappa B, on the circulatory failure and multiple organ dysfunction caused by endotoxin in the rat.
Acidosis, Renal Tubular
Hyperkalemia induced by indomethacin and naproxen and reversed by fludrocortisone.
Acne Vulgaris
Decreased eicosapentaenoic acid levels in acne vulgaris reveals the presence of a proinflammatory state.
Immunohistochemical Expression of Cyclo-oxygenase 2 and Liver X Receptor-? in Acne Vulgaris.
Induction of inflammatory reactions by lipopolysaccharide in hamster sebaceous glands and pilosebaceous units in vivo and in vitro.
Management of premenstrual acne with Cox-2 inhibitors: a placebo controlled study.
Acquired Immunodeficiency Syndrome
Indomethacin enhances the proliferation of mitogen-stimulated T lymphocytes of homosexual males with persistent generalized lymphadenopathy.
Acute Coronary Syndrome
A randomized, placebo-controlled, crossover study of E5510 and aspirin in healthy volunteers.
Associations between COX-2 polymorphisms, blood cholesterol and risk of acute coronary syndrome.
Biomarkers and Bioassays for Cardiovascular Diseases: Present and Future.
Common polymorphisms of cyclooxygenase-2 and prostaglandin E2 receptor and increased risk for acute coronary syndrome in coronary artery disease.
Cyclooxygenase and prostaglandin synthases: roles in plaque stability and instability in humans.
Cyclooxygenase-2 expression and inhibition in atherothrombosis.
Cyclooxygenase-2 inhibitors and coronary occlusion--exploring dose-response relationships.
Cyclooxygenase-2 inhibitors: are they really atherothrombotic, and if not, why not?
Divergent effects of rofecoxib on endothelial function and inflammation in acute coronary syndromes.
Effects of short-term anti-inflammatory therapy on endothelial function in patients with non-ST-segment elevation acute coronary syndrome.
Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study.
Genetic and Molecular Determinants of Atherosclerotic Plaque Instability.
Greater collagen-induced platelet aggregation following cyclooxygenase 1 inhibition predicts incident acute coronary syndromes.
Meta-Analysis of the Role of Cangrelor for Patients Undergoing Percutaneous Coronary Intervention.
Novel determinants of plaque instability.
Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Platelet-derived 12-hydroxyeicosatetraenoic acid plays an important role in mediating canine coronary thrombosis by regulating platelet glycoprotein IIb/IIIa activation.
Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy.
Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes.
Role of Platelets and Antiplatelet Therapy in Cardiovascular Disease.
The risk of coronary thrombosis with cyclo-oxygenase-2 inhibitors does not vary with polymorphisms in two regions of the cyclo-oxygenase-2 gene.
Vorapaxar in the secondary prevention of atherothrombosis.
[Expression of COX-2 and pregnancy associate plasma protein A in coronary arteries and their relationship with acute coronary syndrome: an autopsy study of 42 cases]
[Protective effect of lornoxicam on development of myocardial infarction in rats under conditions of ischemia and ischemia-reperfusion]
[Role of anti-inflammatory drugs in the treatment of acute coronary syndromes. From athero-inflammation to athero-thrombosis]
[Significance and expression of cyclooxygenase-2 mRNA in peripheral blood monocytes in patients with acute coronary syndrome]
[Specific cyclo-oxygenase-2 inhibitors in cardiovascular pathology]
Acute Kidney Injury
Acute renal failure after administration of a single dose of a highly selective COX-2 inhibitor.
Acute renal failure and hyperkalaemia associated with cyclooxygenase-2 inhibitors.
Acute renal failure from hemoglobinuric and interstitial nephritis secondary to iodine and mefenamic acid.
Adverse Effects of Oral Nonselective and cyclooxygenase-2-Selective NSAIDs on Hospitalization for Acute Kidney Injury: A Nested Case-Control Cohort Study.
Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis.
Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol).
COX-2 inhibition attenuates endotoxin-induced downregulation of organic anion transporters in the rat renal cortex.
COX-2 inhibitor induced anuric renal failure in a previously healthy young woman.
Cyclooxygenase-2 and hypoxia-regulated proteins are modulated by basic fibroblast growth factor in acute renal failure.
Cyclooxygenase-2 inhibitor-associated acute renal failure: case report with rofecoxib and review of the literature.
Do non-steroidal anti-inflammatory drugs and COX-2 selective inhibitors have different renal effects?
Effect of Caffeic Acid on Ischemia-Reperfusion-Induced Acute Renal Failure in Rats.
Endothelial prostacyclin protects the kidney from ischemia-reperfusion injury.
Inhibition of glycogen synthase kinase-3? prevents NSAID-induced acute kidney injury.
Modulation of inflammatory response by selective inhibition of cyclooxygenase-1 and cyclooxygenase-2 in acute kidney injury.
Nephrotoxicity related to new therapeutic compounds.
Nephrotoxicity with cyclooxygenase 2 inhibitor use in children.
Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury.
Perioperative COX-2 inhibitors may increase the risk of post-operative acute kidney injury.
Profound urinary protein loss and acute renal failure caused by cyclooxygenase-2 inhibitor.
Prostacyclin in endotoxemia-induced acute kidney injury: cyclooxygenase inhibition and renal prostacyclin synthase transgenic mice.
Protective Effect of Taurine on Mice with Doxorubicin-induced Acute Kidney Injury.
Renal cyclooxygenase-2 (COX-2). Physiological, pathophysiological, and clinical implications.
Renal failure associated with the use of celecoxib and rofecoxib.
Selective cyclooxygenase-2 inhibitor use and progression of renal function in patients with chronic kidney disease: a single-center retrospective cohort study.
[Medication-induced impairment of renal function: what is important?]
Acute Lung Injury
Anti-Inflammatory Effects of Apigenin in Lipopolysaccharide-Induced Inflammatory in Acute Lung Injury by Suppressing COX-2 and NF-kB Pathway.
Bronchial circulation and cyclooxygenase products in acute lung injury.
Components of diesel exhaust particles differentially affect lung expression of cyclooxygenase-2 related to bacterial endotoxin.
Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury.
Cyclooxygenase and lipoxygenase inhibition by BW-755C reduces acrolein smoke-induced acute lung injury.
Cyclooxygenase inhibition prevents PMA-induced increases in lung vascular permeability.
Cyclooxygenase inhibitors prevent ethchlorvynol-induced injury in rat and rabbit lungs.
Cyclooxygenase-2 suppresses polymorphonuclear neutrophil apoptosis after acute lung injury.
Dexamethasone Attenuates LPS-induced Acute Lung Injury through Inhibition of NF-?B, COX-2, and Pro-inflammatory Mediators.
Effect of cyclooxygenase inhibition on ethchlorvynol-induced acute lung injury in dogs.
Effect of eicosanoid inhibition on the development of pulmonary edema after acute lung injury.
Effects of 15-deoxy-delta12,14-prostaglandin J2 on the cyclooxygenase-2 expression in the murine lung in the presence of lipopolysaccharide.
Enhanced microvascular permeability of PMA-induced acute lung injury is not mediated by cyclooxygenase products.
Ginkgo biloba extracts attenuate lipopolysaccharide-induced inflammatory responses in acute lung injury by inhibiting the COX-2 and NF-?B pathways.
Glycyrrhizin treatment is associated with attenuation of lipopolysaccharide-induced acute lung injury by inhibiting cyclooxygenase-2 and inducible nitric oxide synthase expression.
Hydrogen sulfide upregulates cyclooxygenase-2 and prostaglandin E metabolite in sepsis-evoked acute lung injury via transient receptor potential vanilloid type 1 channel activation.
Ibuprofen reduces ethchlorvynol lung injury: possible role of blood flow distribution.
Influence of cyclooxygenase and lipoxygenase inhibitors on oxidative stress-induced lung injury.
Lipoxin A(4) regulates bronchial epithelial cell responses to acid injury.
Matrine Attenuates COX-2 and ICAM-1 Expressions in Human Lung Epithelial Cells and Prevents Acute Lung Injury in LPS-Induced Mice.
Mediators of lung injury in mice following systemic activation of complement.
Medical treatment of pulmonary hypertension in acute lung disease.
Meta-analysis: Methods, strengths, weaknesses, and political uses.
Prostaglandins PGE(2) and PGI(2) promote endothelial barrier enhancement via PKA- and Epac1/Rap1-dependent Rac activation.
Prostaglandins potentiate U-46619-induced pulmonary microvascular dysfunction.
Protective Effect of Isorhamnetin on Lipopolysaccharide-Induced Acute Lung Injury in Mice.
Role of cyclooxygenase-2 in oleic acid-induced acute lung injury.
Shikonin attenuates lipopolysaccharide-induced acute lung injury in mice.
Substance P Upregulates Cyclooxygenase-2 and Prostaglandin E Metabolite by Activating ERK1/2 and NF-{kappa}B in a Mouse Model of Burn-Induced Remote Acute Lung Injury.
The neutrophil respiratory burst and tissue injury in septic acute lung injury: the effect of cyclooxygenase inhibition in swine.
The pulmonary circulation in acute lung injury: a review of some recent advances.
The role of cyclooxygenase-2 in mechanical ventilation-induced lung injury.
[Cyclooxygenase 2 derived lipid mediators play a pivotal role in resolution of acute lung injury]
[Effects of vasoactive cyclooxygenase products on shunt flow and extravascular lung water in acute lung injuries]
[Prostanoids and acute lung injury]
[Protective mechanisms of sevoflurane against one-lung ventilation-induced acute lung injury: role of cyclooxygenase-2 and 5-lipoxygenase pathways].
[The effect of cyclooxygenase-2 inhibitor on acute lung injury]
[The effect of nitric oxide inhalation on the expression of COX-2 and toll-like receptor 4 in rat acute lung injury induced by lipopolysaccharide]
Acute-On-Chronic Liver Failure
[Expression of COX-2 and PPARr in the livers of patients with acute on chronic HBV-related liver failure and their relationship with clinic parameters].
Adenocarcinoma
-765G > C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia.
11-Oxoeicosatetraenoic acid is a cyclooxygenase-2/15-hydroxyprostaglandin dehydrogenase-derived antiproliferative eicosanoid.
15-Hydroxyprostaglandin dehydrogenase as a marker in colon carcinogenesis: analysis of the prostaglandin pathway in human colonic tissue.
5-Lipoxygenase is Coexpressed with Cox-2 in Sporadic Colorectal Cancer: A Correlation with Advanced Stage.
A celecoxib derivative potently inhibits proliferation of colon adenocarcinoma cells by induction of apoptosis.
A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma.
A higher dietary ratio of long-chain omega-3 to total omega-6 fatty acids for prevention of COX-2-dependent adenocarcinomas.
A medicinal extract of Scutellaria baicalensis and Acacia catechu acts as a dual inhibitor of cyclooxygenase and 5-lipoxygenase to reduce inflammation.
A nitrophenyl-based prodrug type for colorectal targeting of prednisolone, budesonide and celecoxib.
A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer.
A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer.
A positive feedback loop that regulates cyclooxygenase-2 expression and prostaglandin F2alpha synthesis via the F-series-prostanoid receptor and extracellular signal-regulated kinase 1/2 signaling pathway.
A role for cAMP-driven transactivation of EGFR in cancer aggressiveness - therapeutic implications.
Acid increases proliferation via ERK and p38 MAPK-mediated increases in cyclooxygenase-2 in Barrett's adenocarcinoma cells.
Acid suppression and chemoprevention in Barrett's oesophagus.
Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors.
Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition.
Alterations of COX-2, HER-2/neu and E-Cadherin protein expression in the prostatic adenocarcinoma: preliminary findings.
Altered expression of beta-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis.
An immunohistochemical study of cyclooxygenase-2 expression in various feline neoplasms.
An investigation of the rate of cyclooxygenase-2 expression on the surface of adenomatous and colorectal adenocarcinoma polyps.
Angiogenic markers, neovascularization and malignant deformation of Barrett's esophagus.
Anti-reflux anastomosis following esophagectomy for adenocarcinoma of the esophagogastric junction: impact of duodenogastroesophageal reflux and expression of cyclooxygenase-2 in the remnant esophagus.
Antioxidant activities of extracts from five anti-viral medicinal plants.
Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro(1).
Antitumor activity in a rat mammary adenocarcinoma: the effect of cyclooxygenase inhibitors and immunization against prostaglandin E2.
Antitumor effect of the selective COX-2 inhibitor celecoxib on endometrial adenocarcinoma in vitro and in vivo.
Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction.
Apoptotic effects of two COX-2 inhibitors on breast adenocarcinoma cells through COX-2 independent pathway.
Aspirin and non-small cell lung cancer resections: effect on long-term survival.
Association Between COX-2 Expression and Effectiveness of COX-2 Inhibitors in a Phase II Trial in Patients with Metastatic Colorectal Adenocarcinoma.
Barrett esophagus.
Barrett's esophagus: chemoprevention.
beta-Carotene downregulates the steady-state and heregulin-alpha-induced COX-2 pathways in colon cancer cells.
Bile acids are multifunctional modulators of the Barrett's carcinogenesis.
Bile acids induce cyclooxygenase-2 expression in human pancreatic cancer cell lines.
Bombesin induces cyclooxygenase-2 expression through the activation of the nuclear factor of activated T cells and enhances cell migration in Caco-2 colon carcinoma cells.
Briarane Diterpenes Diminish COX-2 Expression in Human Colon Adenocarcinoma Cells.
Canonical Wnt Signaling Pathway Plays an Essential Role in N-Methyl-N-Nitrosurea Induced Gastric Tumorigenesis of Mice.
Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts.
Celecoxib synergizes human pancreatic ductal adenocarcinoma cells to sorafenib-induced growth inhibition.
Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells.
Cell Intrinsic Role of Cox-2 in Pancreatic Cancer Development.
Characterization of the Prostaglandin E2 path way in a Rat Model of Esophageal Adenocarcinoma.
Chemoprevention for Barrett's esophagus trial. Design and outcome measures.
Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus.
Chemopreventive effect of protein extract of Asterina pectinifera in HT-29 human colon adenocarcinoma cells.
Chemopreventive effects of polysaccharides extract from Asterina pectinifera on HT-29 human colon adenocarcinoma cells.
Chicken Skin Mucosa Surrounding Adult Colorectal Adenomas is a Risk Factor for Carcinogenesis.
Clinical and prognosis relevance of COX-2 expression in Tunisian patients with primary gastric adenocarcinoma.
Clinicopathologic association of cyclooxygenase 1 and cyclooxygenase 2 expression in gastric adenocarcinoma.
Clinicopathological Correlations of Cyclooxygenase-2, MDM2, and p53 Expressions in Surgically Resectable Pancreatic Invasive Ductal Adenocarcinoma.
Co-expression of beta-adrenergic receptors and cyclooxygenase-2 in pulmonary adenocarcinoma.
Co-expression of Cox-2 and EGFR in stage I human bronchial adenocarcinomas.
Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma.
Coexpression of VEGF-C and Cox-2 in human colorectal cancer and its association with lymph node metastasis.
Cohort study of COX-1 and COX-2 expression in canine rectal and bladder tumours.
Colocalization of BAX with BID and VDAC-1 in nimesulide-induced apoptosis of human colon adenocarcinoma COLO 205 cells.
Colonic adenocarcinomas rapidly induced by the combined treatment with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and dextran sodium sulfate in male ICR mice possess beta-catenin gene mutations and increases immunoreactivity for beta-catenin, cyclooxygenase-2 and inducible nitric oxide synthase.
Colorectal cancer and nonsteroidal anti-inflammatory drugs.
Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/beta-catenin/cyclin D1 signaling pathway in rats.
Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer.
Comparative ability of ibuprofen and N-(4-hydroxyphenyl)retinamide to inhibit development of rat mammary adenocarcinomas associated with differential inhibition of gene expression of cyclooxygenase isoforms.
Comparative analysis of clinicopathological correlations of cyclooxygenase-2 expression in resectable pancreatic cancer.
Comparison of COX-2, Ki-67, and BCL-2 expression in normal esophageal mucosa, Barrett's esophagus, dysplasia, and adenocarcinoma with postablation mucosa and implications for ablative therapies.
Comparison of cyclooxygenase 2 expression in adenocarcinomas of the gastric cardia and distal oesophagus.
Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors.
Coordinate up-regulation of low-density lipoprotein receptor and cyclo-oxygenase-2 gene expression in human colorectal cells and in colorectal adenocarcinoma biopsies.
Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer.
Correlation between expression of cyclooxygenase-2 and angiogenesis in human gastric adenocarcinoma.
Correlation Between Inducible Nitric Oxide Synthase and Cyclooxygenase-2 Expression in Human Colorectal Adenocarcinoma: A Cross-Sectional Study.
Correlation of COX- 2 Expression in Colorectal Carcinoma with Clinicopathological Features.
COX-2 and p53 in human sinonasal cancer: COX-2 expression is associated with adenocarcinoma histology and wood-dust exposure.
COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma.
COX-2 CA-Haplotype Is a Risk Factor for the Development of Esophageal Adenocarcinoma.
COX-2 expression in canine anal sac adenocarcinomas and in non-neoplastic canine anal sacs.
COX-2 gene expression and methylation profile in Sapajus apella as an experimental model for gastric adenocarcinoma.
Cox-2 in non-small cell lung cancer: A meta-analysis.
COX-2 induction by unconjugated bile acids involves reactive oxygen species-mediated signalling pathways in Barrett's oesophagus and oesophageal adenocarcinoma.
COX-2 inhibition and lung cancer.
COX-2 inhibition in esophagitis, Barrett's esophagus and esophageal cancer.
COX-2 is expressed in human pulmonary, colonic, and mammary tumors.
COX-2 mediates pro-tumorigenic effects of PKC? in prostate cancer.
COX-2 overexpression in resected pancreatic head adenocarcinomas correlates with favourable prognosis.
COX-2 polymorphisms and colorectal cancer risk: a strategy for chemoprevention.
COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus.
COX-2, inflammatory secreted PLA2, and cytoplasmic PLA2 protein expression in small bowel adenocarcinomas compared with colorectal adenocarcinomas.
COX-2, MMP-9, and Noguchi classification provide additional prognostic information about adenocarcinoma of the lung. A study of 117 patients from Brazil.
COX-2/EGFR expression and survival among women with adenocarcinoma of the lung.
COX2 expression, angiogenesis, proliferation and survival in Barrett's cancer.
CS-706, a novel cyclooxygenase-2 selective inhibitor, prolonged the survival of tumor-bearing mice when treated alone or in combination with anti-tumor chemotherapeutic agents.
CUGBP2 plays a critical role in apoptosis of breast cancer cells in response to genotoxic injury.
Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells.
Cyclo-oxygenase-2 expression in esophageal adenocarcinoma as a determinant of clinical outcome following esophagectomy.
Cyclo-oxygenase-2 expression in primary cancers of the lung and bladder compared to normal adjacent tissue.
Cyclo-oxygenase-2 expression is associated with mean standardised uptake value on 18F-Fluorodeoxyglucose positron emission tomography in oesophageal adenocarcinoma.
Cyclo-oxygenase-2 over-expression is associated with human esophageal squamous cell carcinoma.
Cyclooxigenase-2 Levels are Increased in the Lung Tissue and Bronchial Tumors of Patients with Chronic Obstructive Pulmonary Disease.
Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure.
Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging.
Cyclooxygenase 2, p53, beta-catenin, and APC protein expression in gastric adenomatous polyps.
Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps.
Cyclooxygenase 2-mediated apoptotic and inflammatory responses in photodynamic therapy treated breast adenocarcinoma cells and xenografts.
Cyclooxygenase 2: from inflammation to carcinogenesis.
Cyclooxygenase inhibitors decrease the growth and induce regression of human esophageal adenocarcinoma xenografts in nude mice.
Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysis.
Cyclooxygenase Isoenzyme-2 and Vascular Endothelial Growth Factor are Associated with Poor Prognosis in Esophageal Adenocarcinoma.
Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats.
Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1.
Cyclooxygenase-2 (COX-2) expression in human endometrial carcinoma and precursor lesions and its possible use in cancer chemoprevention and therapy.
Cyclooxygenase-2 (COX-2) is the key event in pathophysiology of Barrett's esophagus. Lesson from experimental animal model and human subjects.
Cyclooxygenase-2 (COX-2) mRNA expression levels in normal lung tissues and non-small cell lung cancers.
Cyclooxygenase-2 (COX2) expression in adenocarcinoma surpasses that of squamous cell carcinoma in the uterine cervix.
Cyclooxygenase-2 and B-cell lymphoma-2 expression in cystitis glandularis and primary vesicle adenocarcinoma.
Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays.
Cyclooxygenase-2 and epidermal growth factor receptor expressions in different histological subtypes of cervical carcinomas.
Cyclooxygenase-2 and epithelial growth factor receptor up-regulation during progression of Barrett's esophagus to adenocarcinoma.
Cyclooxygenase-2 and gastric carcinogenesis.
Cyclooxygenase-2 and Inducible Nitric Oxide Synthase Gene Polymorphisms and Risk of Reflux Esophagitis, Barrett's Esophagus, and Esophageal Adenocarcinoma.
Cyclooxygenase-2 and prostate carcinogenesis.
Cyclooxygenase-2 expression and cell proliferation are increased in MUC2-positive area of columnar-lined esophagus.
Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1-deficient mice.
Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors.
Cyclooxygenase-2 expression correlates with angiogenesis and apoptosis in gastric cancer tissue.
Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer.
Cyclooxygenase-2 expression during carcinogenesis in the human stomach.
Cyclooxygenase-2 expression in canine mammary tumors.
Cyclooxygenase-2 expression in esophageal epithelium before and after photodynamic therapy for Barrett's esophagus with high-grade dysplasia or intramucosal carcinoma.
Cyclooxygenase-2 expression in feline pancreatic adenocarcinomas.
Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia.
Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions.
Cyclooxygenase-2 expression in human adenocarcinoma cell line HT29 cl.19A.
Cyclooxygenase-2 expression in human esophageal carcinoma.
Cyclooxygenase-2 expression in human pancreatic adenocarcinomas.
Cyclooxygenase-2 expression in spontaneous intestinal neoplasia of domestic dogs.
Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.
Cyclooxygenase-2 expression is abundant in alveolar type II cells in lung cancer-sensitive mouse strains and in premalignant lesions.
Cyclooxygenase-2 expression is associated with histologic tumor type in canine mammary carcinoma.
Cyclooxygenase-2 expression is related to prognosis in patients with esophageal squamous cell carcinoma.
Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer.
Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer.
Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer.
Cyclooxygenase-2 in Barrett's esophagus, Barrett's adenocarcinomas, and esophageal SCC: ready for clinical trials.
Cyclooxygenase-2 in human non-small cell lung cancer.
Cyclooxygenase-2 inhibition as a strategy for treating gastric adenocarcinoma.
Cyclooxygenase-2 inhibition in colon experimental carcinogenesis.
Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines.
Cyclooxygenase-2 inhibitor NS398 enhances antitumor effect of irradiation on hormone refractory human prostate carcinoma cells.
Cyclooxygenase-2 inhibitor therapy for the prevention of esophageal adenocarcinoma in Barrett's esophagus.
Cyclooxygenase-2 inhibitors demonstrate anti-proliferative effects in oesophageal cancer cells by prostaglandin E(2)-independent mechanisms.
Cyclooxygenase-2 inhibitors in lung cancer.
Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR.
Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma.
Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma.
Cyclooxygenase-2 plays a suppressive role for induction of apoptosis in isoliquiritigenin-treated mouse colon cancer cells.
Cyclooxygenase-2 up-regulation after FLAP transfection in human adenocarcinoma cell line HT29 cl.19A.
Cyclooxygenase-2: a possible target in schistosoma-associated bladder cancer.
Cyclooxygenase-independent induction of p21WAF-1/cip1, apoptosis and differentiation by L-745,337, a selective PGH synthase-2 inhibitor, and salicylate in HT-29 cells.
Cytoplasmic phospholipase A2 alpha overexpression in stromal cells is correlated with angiogenesis in human colorectal cancer.
Cytoplasmic phospholipase A2 expression in human colon adenocarcinoma is correlated with cyclooxygenase-2 expression and contributes to prostaglandin E2 production.
Cytotoxicity of selected novel chalcone derivatives on human breast, lung and hepatic carcinoma cell lines.
Deoxycholate induces COX-2 expression via Erk1/2-, p38-MAPK and AP-1-dependent mechanisms in esophageal cancer cells.
Dietary administration with prenyloxycoumarins, auraptene and collinin, inhibits colitis-related colon carcinogenesis in mice.
Differential cyclooxygenase-2 expression in squamous cell carcinoma and adenocarcinoma of the uterine cervix.
Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid.
Dihydroxy bile acids activate the transcription of cyclooxygenase-2.
Direct growth-inhibitory effects of prostaglandin E2 in pancreatic cancer cells in vitro through an EP4/PKA-mediated mechanism.
Discrepancies in expression and prognostic value of tumor markers in adenocarcinoma and squamous cell carcinoma in cervical cancer.
Down-regulation of prostaglandin E2 by curcumin is correlated with inhibition of cell growth and induction of apoptosis in human colon carcinoma cell lines.
Early-onset gastric cancers have a different molecular expression profile than conventional gastric cancers.
Effect of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of lung tumors and their expression of cyclooxygenase-2 and peroxisome proliferator- activated receptor-gamma.
Effect of adiponectin and ghrelin on apoptosis of Barrett adenocarcinoma cell line.
Effect of celecoxib plus standard chemotherapy on serum levels of vascular endothelial growth factor and cyclooxygenase-2 in patients with gastric cancer.
Effect of the specific cyclooxygenase-2 inhibitor meloxicam on tumour growth and cachexia in a murine model.
Effects of Celebrex and Zyflo on liver metastasis and lipidperoxidation in pancreatic cancer in Syrian hamsters.
Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis.
Effects of combined octreotide and aspirin on the growth of gastric cancer.
Effects of cyclooxygenase-2 inhibition on serum and tumor gastrins and expression of apoptosis-related proteins in colorectal cancer.
Effects of NSAIDs on proliferation of gastric cancer cells in vitro: possible implication of cyclooxygenase-2 in cancer development.
Efficacy of Dimethylaminoparthenolide and Sulindac in Combination With Gemcitabine in a Genetically Engineered Mouse Model of Pancreatic Cancer.
EGF-R is expressed and AP-1 and NF-kappaB are activated in stromal myofibroblasts surrounding colon adenocarcinomas paralleling expression of COX-2 and VEGF.
EGFR, but not COX-2, protein in resected pancreatic ductal adenocarcinoma is associated with poor survival.
Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma.
Elevated expression of cyclooxygenase-2 in adenocarcinoma of the parotid gland: insights into malignant transformation of pleomorphic adenoma.
Elevation of cyclooxygenase-2 is related to lymph node metastasis in adenocarcinoma of uterine cervix.
Enhanced inhibitive effects of combination of rofecoxib and octreotide on the growth of human gastric cancer.
Expression and localization of cyclo-oxygenase isoforms in non-small cell lung cancer.
Expression and significance of cyclooxygenase 2 gene in lung cancer.
Expression of apoptosis-related proteins in Barrett's metaplasia-dysplasia-carcinoma sequence: a switch to a more resistant phenotype.
Expression of BMP2, TLR3, TLR4 and COX2 in colorectal polyps, adenoma and adenocarcinoma.
Expression of COX-2 and E-cadherin in Tunisian patients with colorectal adenocarcinoma.
Expression of COX-2 and PGE synthase and synthesis of PGE(2)in endometrial adenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors.
Expression of COX-2 in stomach cancers and its relation to their biological features.
Expression of COX-2 in Stomach Carcinogenesis.
Expression of COX-2 is associated with accumulation of p53 in pancreatic cancer: analysis of COX-2 and p53 expression in premalignant and malignant ductal pancreatic lesions.
Expression of cyclo-oxygenase 1 and 2, prostaglandin E synthase and transforming growth factor beta1, and their relationship with vascular endothelial growth factors A and C, in primary adenocarcinoma of the small intestine.
Expression of cyclooxygenase 2 and vascular endothelial growth factor in gastric carcinoma: Relationship with clinicopathological parameters.
Expression of cyclooxygenase 2 by prostaglandin E(2) in human endometrial adenocarcinoma cell line HEC-1B.
Expression of cyclooxygenase-2 (COX-2) in colorectal adenocarcinoma: an immunohistochemical and histopathological study.
Expression of cyclooxygenase-2 and clinicopathologic features in human gastric adenocarcinoma.
Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas.
Expression of Cyclooxygenase-2 and Tumor Microvessel Density in Colorectal Cancer.
Expression of cyclooxygenase-2 and vascular endothelial growth factor in pancreatic tumors.
Expression of cyclooxygenase-2 has no impact on survival in adenocarcinoma of the esophagogastric junction but is associated with favourable clinicopathologic features.
Expression of cyclooxygenase-2 in adenocarcinomas of the uterine cervix and its relation to angiogenesis and tumor growth.
Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies.
Expression of cyclooxygenase-2 in colorectal adenocarcinoma is associated with p53 accumulation and hdm2 overexpression.
Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma.
Expression of cyclooxygenase-2 in endometrial adenocarcinoma.
Expression of cyclooxygenase-2 in human adenocarcinomas of the gastric cardia and corpus.
Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas.
Expression of cyclooxygenase-2 in human gastric carcinoma.
Expression of cyclooxygenase-2 in human lung carcinoma.
Expression of cyclooxygenase-2 in ovarian mature cystic teratomas with malignant transformation.
Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia.
Expression of cyclooxygenase-2 is associated with p53 accumulation in premalignant and malignant gallbladder lesions.
Expression of cyclooxygenase-2 protein in gastric adenocarcinoma.
Expression of Cyclooxygenase-2 Protein in Gastric Carcinogenesis.
Expression of cyclooxygenase-2, Fas and Fas ligand in pulmonary adenocarcinoma and atypical adenomatous hyperplasia.
Expression of HuR, COX-2, and survivin in lung cancers; cytoplasmic HuR stabilizes cyclooxygenase-2 in squamous cell carcinomas.
Expression of inducible nitric oxide synthase and cyclooxygenase-2 in angiogenesis and clinical outcome of human gastric cancer.
Expression of inducible nitric oxide synthase and cyclooxygenase-2 in pancreatic adenocarcinoma: correlation with microvessel density.
Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters.
Expression of nitric oxide synthase, cyclooxygenase, and p53 in different stages of human gastric cancer.
Expression of oestrogen receptors, ERalpha, ERbeta, and ERbeta variants, in endometrial cancers and evidence that prostaglandin F may play a role in regulating expression of ERalpha.
Expression of p-Akt and COX-2 in gastric adenocarcinomas and adenovirus mediated Akt1 and COX-2 ShRNA suppresses SGC-7901 gastric adenocarcinoma and U251 glioma cell growth in vitro and in vivo.
Expression of PCNA, Ki-67 and COX-2 in breast cancer based on DCE-MRI image information.
Expression of prostaglandin G/H synthase type 1, but not type 2, in human ovarian adenocarcinomas.
Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2.
Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas.
Expression Profile as Predictor of Relapse after Adjuvant Treatment in Gastric Cancer.
Expression profiles of Annexin A1, formylated peptide receptors and cyclooxigenase-2 in gastroesophageal inflammations and neoplasias.
F-prostanoid receptor regulation of fibroblast growth factor 2 signaling in endometrial adenocarcinoma cells.
Fatty acid CoA ligase 4 is up-regulated in colon adenocarcinoma.
Fenretinide inhibits phorbol ester-induced cyclooxygenase-2 expression in human colon adenocarcinoma cells.
From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures.
Functional role of beta-adrenergic receptors in the mitogenic action of nicotine on gastric cancer cells.
G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2.
Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis.
Gastroesophageal reflux disease (GERD): current agents and future perspective.
Gastroesophageal reflux disease.
General tolerability and use of nonsteroidal anti-inflammatory drugs.
Growth inhibitory effect of celecoxib and rofecoxib on human colorectal carcinoma cell lines.
Guggulsterone, a plant-derived inhibitor of NF-TB, suppresses CDX2 and COX-2 expression and reduces the viability of esophageal adenocarcinoma cells.
Has Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results.
Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma.
Helicobacter pylori and non-malignant diseases.
Helicobacter pylori infection, gastrin, cyclooxygenase-2, and apoptosis in colorectal cancer.
HER-2, EGFR, COX-2 expression status correlated to microvessel density and survival in resected non-small cell lung cancer.
High cyclooxygenase-2 expression in cervical adenocarcinomas.
High PTGS2 expression in post-neoadjuvant chemotherapy-treated oesophageal adenocarcinoma is associated with improved survival: a population-based cohort study.
hMLH1, hMSH2 and cyclooxygenase-2 (cox-2) in sporadic colorectal polyps.
Human colorectal adenomas demonstrate a size-dependent increase in epithelial cyclooxygenase-2 expression.
HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.
Hypoxia and prostaglandin E receptor 4 signalling pathways synergise to promote endometrial adenocarcinoma cell proliferation and tumour growth.
Hypoxia-inducible factor-2? is essential in activating the COX2/mPGES-1/PGE2 signaling axis in colon cancer.
Immunoexpression of cyclooxygenase-1 and -2 in ulcerative colitis.
Immunohistochemical analysis and in situ hybridization of cyclooxygenase-2 expression in intraductal papillary-mucinous tumors of the pancreas.
Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors.
Immunohistochemical analysis of cyclooxygenase-2 expression in premalignant and malignant esophageal glandular and squamous lesions in Cixian, China.
Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors.
Immunohistochemical Expression of Cyclooxygenase-2 (COX-2) in Feline Endometrial Adenocarcinoma and in Normal and Hyperplastic Endometria.
Immunohistochemical expression of p53, Bcl-2, COX-2, C-erb-B2, EPO-R, beta-catenin, and E-cadherin in non tumoral gastric mucous membrane.
Immunohistochemical study of cyclooxygenases in prostatic adenocarcinoma; relationship to apoptosis and Bcl-2 protein expression.
Impact of COX-2, IL-1?, TNF-?, IL-4 and IL-10 on the process of carcinogenesisin the large bowel.
Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung.
Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs.
Increased cyclooxygenase-2 expression is correlated with suppressed antitumor immunity in cervical adenocarcinomas.
Increased expression of COX-2 in the development of human lung cancers.
Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas.
Increased expression of cyclooxygenase-2 and Ki-67 are associated with malignant transformation of pleomorphic adenoma.
Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer.
Increased expression of cyclooxygenase-2 correlates with resistance to radiation in human prostate adenocarcinoma cells.
Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors.
Increased expression of cyclooxygenase-2 in rat lung tumors induced by the tobacco-specific nitrosamine 4-(methylnitrosamino)-4-(3-pyridyl)-1-butanone: the impact of a high-fat diet.
Increased expression of cyclooxygenase-2 protein in rat lung tumors induced by N-nitrosobis(2-hydroxypropyl)amine.
Increased expression of cytoplasmic HuR in familial adenomatous polyposis.
Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas.
Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in pancreatic cancer.
Increased protein expression of both inducible nitric oxide synthase and cyclooxygenase-2 in human colon cancers.
Increasing cyclooxygenase-2 (cox-2) gene expression in the progression of Barrett's esophagus to adenocarcinoma correlates with that of Bcl-2.
Indomethacin but not a selective cyclooxygenase-2 inhibitor inhibits esophageal adenocarcinogenesis in rats.
Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome C independent of COX-2 expression.
Induction of prostaglandin G/H synthase-2 in a canine model of spontaneous prostatic adenocarcinoma.
Inflammation and MiR-21 pathways functionally interact to downregulate PDCD4 in colorectal cancer.
Inflammation-associated gene expression is altered between normal human ovarian surface epithelial cells and cell lines derived from ovarian adenocarcinomas.
Inflammation-related carcinogenesis and prevention in esophageal adenocarcinoma using rat duodenoesophageal reflux models.
Influence of age and gender on association between -765G > C COX-2 genetic polymorphism and gastric adenocarcinoma risk: a case-control study in Iran.
Inhibition of apoptosis in normal and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2.
Inhibition of Barret's adenocarcinoma cell growth by simvastatin: involvement of COX-2 and apoptosis-related proteins.
Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via enhancement of TRAIL in human prostate adenocarcinoma xenograft model.
Inhibition of cyclooxygenase-2 by tetramethylpyrazine and its effects on A549 cell invasion and metastasis.
Inhibition of pancreatic and lung adenocarcinoma cell survival by curcumin is associated with increased apoptosis, down-regulation of COX-2 and EGFR and inhibition of Erk1/2 activity.
Inhibition of the biosynthesis of prostaglandin E2 by low dose aspirin: implications for adenocarcinoma metastasis.
Inhibitory effects of adenovirus mediated COX-2, Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo.
Intracellular unesterified arachidonic acid signals apoptosis.
Involvement of COX-2/PGE(2) Pathway in the Upregulation of MMP-9 Expression in Pancreatic Cancer.
JTE-522, a selective cyclooxygenase-2 inhibitor, inhibits induction but not growth and invasion of 1,2-dimethylhydrazine-induced tubular adenocarcinomas of colon in rats.
Lactobacillus acidophilus 74-2 and butyrate induce cyclooxygenase (COX)-1 expression in gastric cancer cells.
Lipoxygenase-5 is overexpressed in prostate adenocarcinoma.
Loss of heterozygosity and immunohistochemistry of adenocarcinomas of the esophagus and gastric cardia.
Malignant salivary gland tumors and cyclo-oxygenase-2: A histopathological and immunohistochemical analysis with implications on histogenesis.
Mechanism of growth inhibitory effects of cyclooxygenase-2 inhibitor-NS398 on cancer cells.
Mechanism of P-glycoprotein Expression in the SGC7901 Human Gastric Adenocarcinoma Cell Line Induced by Cyclooxygenase-2.
Mechanisms involved in the antiproliferative and proapoptotic effects of unsaponifiable fraction of extra virgin olive oil on HT-29 cancer cells.
Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma.
Mitogen-activated protein kinase activation and regulation of cyclooxygenase 2 expression by platelet-activating factor and hCG in human endometrial adenocarcinoma cell line HEC-1B.
Molecular characterization of canine prostaglandin G/H synthase-2 and regulation in prostatic adenocarcinoma cells in vitro.
Molecular Characterization of Canine Prostaglandin G/H Synthase-2 and Regulation in Prostatic Adenocarcinoma Cells in Vitro.
Molecular determinants in targeted therapy for esophageal adenocarcinoma.
Mucinous colon carcinomas with microsatellite instability have a lower microvessel density and lower vascular endothelial growth factor expression.
NADPH oxidase NOX5-S mediates acid-induced cyclooxygenase-2 expression via activation of NF-kappaB in Barrett's esophageal adenocarcinoma cells.
Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma.
NF-kappaB/PPAR gamma and/or AP-1/PPAR gamma 'on/off' switches and induction of CBP in colon adenocarcinomas: correlation with COX-2 expression.
Nicotinamide phosphoribosyltransferase and prostaglandin H2 synthase 2 are up-regulated in human pancreatic adenocarcinoma cells after stimulation with interleukin-1.
Nimesulide inhibits proliferation via induction of apoptosis and cell cycle arrest in human gastric adenocarcinoma cell line.
Nitric oxide synthase, arginase and cyclooxygenase are involved in muscarinic receptor activation in different murine mammary adenocarcinoma cell lines.
NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin.
Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention.
Nuclear factor-kappa B regulates cyclooxygenase-2 expression and cell proliferation in human colorectal carcinoma tissue.
Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma.
Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis.
Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice.
Overexpression of cyclooxygenase-2 protein and its relationship to apoptosis in cervical carcinoma treated with neoadjuvant chemotherapy.
Oxidant-sensitive transcription factor and cyclooxygenase-2 by Helicobacter pylori stimulation in human gastric cancer cells.
Pancreatic stellate cells (PSCs) express cyclooxygenase-2 (COX-2) and pancreatic cancer stimulates COX-2 in PSCs.
Pathologic Features of Colorectal Inflammatory Polyps in Miniature Dachshunds.
PGE(2) receptors and synthesis in human gastric mucosa: perturbation in cancer.
Phenotype of columnar-lined esophagus in rats with esophagogastroduodenal anastomosis: similarity to human Barrett's esophagus.
Phthalate plasticizer di(2-ethyl-hexyl) phthalate induces cyclooxygenase-2 expression in gastric adenocarcinoma cells.
Picfeltarraenin IA inhibits lipopolysaccharide-induced inflammatory cytokine production by the nuclear factor-?B pathway in human pulmonary epithelial A549 cells.
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma.
Polymorphism of -765G > C COX-2 is a risk factor for gastric adenocarcinoma and peptic ulcer disease in addition to H pylori infection: A study from northern India.
Polymorphisms in the genes involved in the arachidonic acid-pathway, fish consumption and the risk of colorectal cancer.
Positional isomers of aspirin are equally potent in inhibiting colon cancer cell growth: differences in mode of cyclooxygenase inhibition.
Possible role of PPAR-? and COX-2 receptor modulators in the treatment of Non-Small Cell lung carcinoma.
Potential role of group X secretory phospholipase A(2) in cyclooxygenase-2-dependent PGE(2) formation during colon tumorigenesis.
Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis.
PPAR-gamma is expressed and NF-kB pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas.
Predictive value of APAF-1 and COX-2 expression in pathologic complete response to neoadjuvant chemoradiotherapy for patients with locally advanced rectal adenocarcinoma.
Preference of Endoscopic Ablation Over Medical Prevention of Esophageal Adenocarcinoma by Patients with Barrett's Esophagus.
Preparation and in vitro evaluation of meloxicam-loaded PLGA nanoparticles on HT-29 human colon adenocarcinoma cells.
Prevalence and clinical relevance of cyclooxygenase-1 and -2 expression in stage IIB cervical adenocarcinoma.
Prevalence and prognostic significance of COX-2 expression in stage IB cervical cancer.
Prevention of cancer in the upper gastrointestinal tract with COX-inhibition. Still an option?
Profiles of prostaglandin biosynthesis in sixteen established cell lines derived from human lung, colon, prostate, and ovarian tumors.
Prognostic and Clinic-Pathological Significances of SCF and COX-2 Expression in Inflammatory and Malignant Prostatic Lesions.
Prognostic role of cyclooxygenase-2 expression in esophageal carcinoma.
Prognostic role of cyclooxygenase-2 in neoadjuvant-treated patients with squamous cell carcinoma of the esophagus.
Prognostic role of host cyclooxygenase and cytokine genotypes in a Caucasian cohort of patients with gastric adenocarcinoma.
Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus.
Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus.
Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas.
Prognostic value of eicosanoid pathways in extrahepatic cholangiocarcinoma.
Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition.
Prostaglandin concentrations and prostaglandin synthetase activity in N-nitrosomethylurea-induced rat mammary adenocarcinoma.
Prostaglandin E(2) and F(2alpha) activate the FP receptor and up-regulate cyclooxygenase-2 expression via the cyclic AMP response element.
Prostaglandin E2 stimulates Fas ligand expression via the EP1 receptor in colon cancer cells.
Prostaglandin EP2 receptor expression is increased in Barrett's esophagus and esophageal adenocarcinoma.
Prostaglandin H synthase expression is variable in human colorectal adenocarcinoma cell lines.
Proteomics-based approach to elucidate the mechanism of antitumor effect of curcumin in cervical cancer.
Quantitative, tissue-specific analysis of cyclooxygenase gene expression in the pathogenesis of Barrett's adenocarcinoma.
Relation of the expression of cyclooxygenase-2 in colorectal adenomas and adenocarcinomas to angiogenesis and prognosis.
Relationship between cyclooxygenase 8473T>C polymorphism and risk of lung cancer: a case-control study.
Relationship between expression and distribution of cyclooxygenase-2 and bcl-2 in human gastric adenocarcinoma.
Relationship between HER-2, COX-2, p53 and clinicopathologic features in gastric adenocarcinoma. Do these biomarkers have any prognostic significance?
Reply to Letter to the Editor: Re: Comparison of COX-2, Ki-67, and BCL-2 expression in normal esophageal mucosa, Barrett's esophagus, dysplasia, and adenocarcinoma with postablation mucosa and implications for ablative therapies (Online First).
Resection and use of a cyclooxygenase-2 inhibitor for treatment of pancreatic adenocarcinoma in a cockatiel.
Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against ?? T cell cytotoxicity.
Resistance to apoptosis and cyclooxygenase-2 expression in a human adenocarcinoma cell line HT29 CL.19A.
Resveratrol directly targets COX-2 to inhibit carcinogenesis.
Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus.
Role of cyclooxygenase-2 in the development and treatment of oesophageal adenocarcinoma.
Role of prostaglandin E2 in the invasiveness, growth and protection of cancer cells in malignant pleuritis.
Selective cyclooxygenase-2 inhibition suppresses basic fibroblast growth factor expression in human esophageal adenocarcinoma.
Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer.
Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells.
Selective inhibition of cyclooxygenase (COX)-2 inhibits endothelial cell proliferation by induction of cell cycle arrest.
Selective inhibition of cyclooxygenase-2 inhibits colon cancer cell adhesion to extracellular matrix by decreased expression of beta1 integrin.
Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells.
Seminal plasma activates cyclooxygenase-2 and prostaglandin E2 receptor expression and signalling in cervical adenocarcinoma cells.
Seminal plasma enhances cervical adenocarcinoma cell proliferation and tumour growth in vivo.
Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention.
Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells.
Signet-ring cell carcinoma of colorectum-current perspectives and molecular biology.
Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma.
Sinomenine inhibits proliferation of SGC-7901 gastric adenocarcinoma cells via suppression of cyclooxygenase-2 expression.
Small primary adenocarcinoma in adenomyosis with nodal metastasis: a case report.
Smoking and COX-2 Functional Polymorphisms Interact to Increase the Risk of Gastric Cardia Adenocarcinoma in Chinese Population.
Sp1 and COX2 expression is positively correlated with a poor prognosis in pancreatic ductal adenocarcinoma.
Sphingosine kinase 1 is up-regulated in colon carcinogenesis.
Spontaneous adenocarcinoma immunoreactive to cyclooxygenase-2 and transforming growth factor-beta1 in the buccal salivary gland of a Richardson's ground squirrel (Spermophilus richardsonii).
Strategy for prevention of cancers of the esophagus.
Subepithelial myofibroblasts express cyclooxygenase-2 in colorectal tubular adenomas.
Sulindac prevents esophageal adenocarcinomas induced by gastroduodenal reflux in rats.
Suppression by nimesulide of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in Wistar rats.
Suppression of cyclooxygenase-2 overexpression by 15S-hydroxyeicosatrienoic acid in androgen-dependent prostatic adenocarcinoma cells.
Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model.
Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancer.
Synthetic and naturally occurring COX-2 inhibitors suppress proliferation in a human oesophageal adenocarcinoma cell line (OE33) by inducing apoptosis and cell cycle arrest.
The ?-adrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor ?B signaling.
The Anti-Tumor Effect of HDAC Inhibition in a Human Pancreas Cancer Model Is Significantly Improved by the Simultaneous Inhibition of Cyclooxygenase 2.
The Dynamic Changes of Gut Microbiota in Muc2 Deficient Mice.
The effect of prostaglandin modulators on prostate tumor growth and metastasis.
The expression of cyclooxygenase-1 and -2 in proliferative endometrium and endometrial adenocarcinoma.
The Expression of HSD17B12 Is Associated with COX-2 Expression and Is Increased in High-Grade Epithelial Ovarian Cancer.
The MIF homologue D-dopachrome tautomerase promotes COX-2 expression through ?-catenin-dependent and -independent mechanisms.
The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis.
The resistance to the tumor suppressive effects of COX inhibitors and COX-2 gene disruption in TRAMP mice is associated with the loss of COX expression in prostate tissue.
The retinoid fenretinide inhibits proliferation and downregulates cyclooxygenase-2 gene expression in human colon adenocarcinoma cell lines.
The risks and benefits of cyclo-oxygenase-2 inhibitors in prostate cancer: a review.
The role of COX-2 in intestinal cancer.
The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia.
The role of cyclooxygenases in inflammation, cancer, and development.
The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma.
Tissue microarray-determined expression profiles of cyclooxygenase-2 in colorectal adenocarcinoma: association with clinicopathological parameters.
Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients.
Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB.
Treatment of feline mammary tumours using chemotherapy, surgery and a COX-2 inhibitor drug (meloxicam): a retrospective study of 23 cases (2002-2007)*.
Tristetraprolin binds to the 3'-untranslated region of cyclooxygenase-2 mRNA. A polyadenylation variant in a cancer cell line lacks the binding site.
Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer.
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas.
Upregulation of cyclooxygenase-2 is associated with activation of the alternative nuclear factor kappa B signaling pathway in colonic adenocarcinoma.
[A study on cyclooxygenase-2 protein expression in esophageal carcinoma and premalignant lesions]
[An experimental study on chemoprevention of esophageal adenocarcinoma by celecoxib, a selective cyclooxygenase-2 inhibitor].
[Application of non-steroidal anti-inflammatory drugs to enhance 5-fluorouracil efficacy in experimental systems].
[Chemoprevention of Barrett's esophagus by celecoxib in rats.]
[Construction of recombinant adenovirus vector expressing shRNAs targeting COX-2, AKT1 and PIK3R1 gene and its inhibition effect on proliferation of human gastric adenocarcinoma]
[Cyclooxygenase (COX)-2 expression in a rat duodenoesophageal reflux model and chemoprevention of adenocarcinoma by the selective COX-2 inhibitor nimesulide]
[Cyclooxygenase-2 expression in female pulmonary adenocarcinoma.]
[Different proteome of human lung adenocarcinoma cells treated with NS-398 and cisplation.]
[Expression of COX-2 and its prognostic significance in non-small cell lung cancer.]
[Immunohistochemical markers as prognosticators in gynecologic oncology]
[Influence of selective cyclooxygenase-2 inhibitor on proliferation of human gastric cancer cells]
[Inhibitory effects of targeting protein kinase B1 and cyclooxygenase-2 shRNA upon human gastric adenocarcinoma cell growth]
[Overexpression of COX-2 and a potential clinical application of its inhibitors in lung cancer]
[Overexpression of COX-2 and its clinical significance in non-small cell lung cancer]
[Prognostic significance of cyclooxygenase (COX-1 and COX-2) expression in endometrial carcinoma (clinical and immunohistochemical study)]
[Prognostic significance of cyclooxygenase 2 expression in adenocarcinoma of the esophagus]
[Role of cyclooxygenase-2 in inhibition of human gastric adenocarcinoma cell line SGC-7901 by c9, t11-conjugated linoleic acid]
[Study of COX-2 expression and angiogenesis in non-small cell lung cancer.]
[The effect of siRNA on inhibiting cyclooxygenase-2 gene expression in gastric adenocarcinoma cell]
[The effects of selective cyclooxygenase-2 inhibitors on the growth of gastric adenocarcinoma]
[The Expression of COX-2 in Human Lung Cancer and its Relationship with Expression of K-ras and Mcl-1.]
[The immunohistochemical expression of cyclooxygenase 2 is inversely associated with (18)F-FDG-PET SUV values in non-small-cell lung cancers. Initial results]
Adenocarcinoma of Lung
Activation of thromboxane receptor alpha induces expression of cyclooxygenase-2 through multiple signaling pathways in A549 human lung adenocarcinoma cells.
Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2.
Anti-cancer effect of celecoxib and aerosolized docetaxel against human non-small cell lung cancer cell line, A549.
Anti-Cancer Effects of a New Docosahexaenoic Acid Monoacylglyceride in Lung Adenocarcinoma.
Arsenite pretreatment attenuates benzo[a]pyrene cytotoxicity in a human lung adenocarcinoma cell line by decreasing cyclooxygenase-2 levels.
Bronchioloalveolar carcinoma (lepidic growth) component is a more useful prognostic factor than lymph node metastasis.
Carvacrol encapsulated nanocarrier/ nanoemulsion abrogates angiogenesis by downregulating COX-2, VEGF and CD31 in vitro and in vivo in a lung adenocarcinoma model.
Cinobufocini inhibits NF-?B and COX-2 activation induced by TNF-? in lung adenocarcinoma cells.
Comparative Expression of Apoptotic Markers in Lung Adenocarcinoma and Squamous Cell Carcinoma.
Cooking oil fumes improve lung adenocarcinoma cell survival through c-IAP2 induction.
Cyclooxygenase-2 expression is abundant in alveolar type II cells in lung cancer-sensitive mouse strains and in premalignant lesions.
Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma.
Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway.
Cyclooxygenase-2 inhibition decreases primary and metastatic tumor burden in a murine model of orthotopic lung adenocarcinoma.
Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer.
Difference in prognostic values of maximal standardized uptake value on fluorodeoxyglucose-positron emission tomography and cyclooxygenase-2 expression between lung adenocarcinoma and squamous cell carcinoma.
Downregulation of COX-2 and iNOS by amentoflavone and quercetin in A549 human lung adenocarcinoma cell line.
Downregulation of NMI promotes tumor growth and predicts poor prognosis in human lung adenocarcinomas.
Effects of Feiyanning Decoction, a compound traditional Chinese medicine, on iNOS and COX-2 expressions induced by tumor necrosis factor-? in lung adenocarcinoma cell line.
EGF stimulates cyclooxygenase-2 expression through the STAT5 signaling pathway in human lung adenocarcinoma A549 cells.
Evaluation of an aerosolized selective COX-2 inhibitor as a potentiator of doxorubicin in a non-small-cell lung cancer cell line.
Expression and localization of cyclo-oxygenase isoforms in non-small cell lung cancer.
Expression of cyclooxygenase-2 in human lung carcinoma.
Frequent co-localization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas.
Galectin-1 Promotes Lung Cancer Progression and Chemoresistance by Upregulating p38 MAPK, ERK, and Cyclooxygenase-2.
Histone deacetylase inhibitors and transforming growth factor-beta induce 15-hydroxyprostaglandin dehydrogenase expression in human lung adenocarcinoma cells.
Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via VEGF-C.
Inhibition of pancreatic and lung adenocarcinoma cell survival by curcumin is associated with increased apoptosis, down-regulation of COX-2 and EGFR and inhibition of Erk1/2 activity.
Inhibition of the biosynthesis of prostaglandin E2 by low dose aspirin: implications for adenocarcinoma metastasis.
Interferon gamma induces prostaglandin G/H synthase-2 through an autocrine loop via the epidermal growth factor receptor in human bronchial epithelial cells.
Ku80 cooperates with CBP to promote COX-2 expression and tumor growth.
Maximal standardized uptake value on FDG-PET is correlated with cyclooxygenase-2 expression in patients with lung adenocarcinoma.
MMP-7 is upregulated by COX-2 and promotes proliferation and invasion of lung adenocarcinoma cells.
Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.
NF-kappaB-dependent transcriptional activation in lung carcinoma cells by farnesol involves p65/RelA(Ser276) phosphorylation via the MEK-MSK1 signaling pathway.
NS-398 enhances the efficacy of gemcitabine against lung adenocarcinoma through up-regulation of p21WAF1 and p27KIP1 protein.
Oral administration of aflatoxin G? induces chronic alveolar inflammation associated with lung tumorigenesis.
Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas.
Prognostic value of Cox-2 and PD-L1 expression and its relationship with tumor-infiltrating lymphocytes in resected lung adenocarcinoma.
Prostaglandin E-Major Urinary Metabolite (PGE-MUM) as a Tumor Marker for Lung Adenocarcinoma.
Prostaglandin E2 activates Src signaling in lung adenocarcinoma cell via EP3.
Protection by quercetin against cooking oil fumes-induced DNA damage in human lung adenocarcinoma CL-3 cells: role of COX-2.
Reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells.
Redox Factor-1 Inhibits Cyclooxygenase-2 Expression via Inhibiting of p38 MAPK in the A549 Cells.
Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.
Resveratrol inhibits the proliferation of A549 cells by inhibiting the expression of COX-2.
Selective cyclooxygenase-2 inhibitors and non-small cell lung cancer.
TGF-? Suppresses COX-2 Expression by Tristetraprolin-Mediated RNA Destabilization in A549 Human Lung Cancer Cells.
The immune modulation of Clara cell-10 in human peripheral monocytes and dendritic cells.
Thromboxane A2 exerts promoting effects on cell proliferation through mediating cyclooxygenase-2 signal in lung adenocarcinoma cells.
Transcriptional regulation of basal cyclooxygenase-2 expression in murine lung tumor-derived cell lines by CCAAT/enhancer-binding protein and activating transcription factor/cAMP response element-binding protein.
Transgenic expression of the forkhead box M1 transcription factor induces formation of lung tumors.
[Cyclooxygenase-2 expression in female pulmonary adenocarcinoma.]
[Effects of RNA interference of COX-2 gene expression on malignant proliferation of A549 cells in vitro]
[Mechanisms of EGF regulation of COX-2 through the STAT5 signaling pathway in human lung adenocarcinoma A549 cells].
[The Effects of Interfering COX-2 Gene Expression on Malignant Proliferation of Human Lung Adenocarcinoma A2 Cell in vitro.]
[The Expression and Clinical Significance of HIF-1?, COX-2 and E-cadherin in Patients with Lung Adenocarcinoma.]
Adenocarcinoma, Bronchiolo-Alveolar
Dietary lipids modulate eicosanoid release and apoptosis of cells of a murine lung alveolar carcinoma.
Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung.
Inhaled indomethacin in bronchorrhea in bronchioloalveolar carcinoma: role of cyclooxygenase.
Adenocarcinoma, Clear Cell
Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas.
Adenocarcinoma, Mucinous
Increased expression of cyclooxygenase-2 in human salivary gland tumors.
Simultaneous adeno- and squamous cell carcinoma with different phenotypic profiles in a rat model of chronic gastroesophageal reflux.
Adenoma
11?-Hydroxysteroid Dehydrogenase Type II is a Potential Target for Prevention of Colorectal Tumorigenesis.
15-Hydroxyprostaglandin dehydrogenase as a marker in colon carcinogenesis: analysis of the prostaglandin pathway in human colonic tissue.
15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors.
?-catenin represses expression of the tumour suppressor 15-prostaglandin dehydrogenase in the normal intestinal epithelium and colorectal tumour cells.
A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: regulation of COX-2 by butyrate.
A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts.
A molecular/epidemiologic analysis of expression of cyclooxygenases 1 and 2, use of nonsteroidal antiinflammatory drugs, and risk of colorectal adenoma.
A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.
A reduced COX-2 expression and a reduced number of pericryptal myofibroblasts are associated with depressed adenoma of the colon.
A study of prostaglandin pathway genes and interactions with current nonsteroidal anti-inflammatory drug use in colorectal adenoma.
Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia.
Allellic variants in regulatory regions of cyclooxygenase-2: association with advanced colorectal adenoma.
Altered expression of beta-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis.
Analysis of cyclooxygenase expression in human colorectal adenomas.
Antitumor activity of the MEK inhibitor trametinib on intestinal polyp formation in Apc(?716) mice involves stromal COX-2.
Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398.
Association between Cyclooxygenase expression and colorectal adenoma characteristics.
Association of Ets-related transcriptional factor E1AF expression with overexpression of matrix metalloproteinases, COX-2 and iNOS in the early stage of colorectal carcinogenesis.
Butyrate suppresses mRNA increase of osteopontin and cyclooxygenase-2 in human colon tumor tissue.
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
Celecoxib and rofecoxib potentiate chronic colitis and premalignant changes in interleukin 10 knockout mice.
Celecoxib for the prevention of sporadic colorectal adenomas.
Celecoxib induces proliferation and Amphiregulin production in colon subepithelial myofibroblasts, activating erk1-2 signaling in synergy with EGFR.
Cell proliferation activity unrelated to COX-2 expression in ovarian tumors.
CG100649, a novel COX-2 inhibitor, inhibits colorectal adenoma and carcinoma growth in mouse models.
Changes in antitumor response in C57BL/6J-Min/+ mice during long-term administration of a selective cyclooxygenase-2 inhibitor.
Chemoprevention in colorectal neoplasias: what is practical and feasible?
Chemoprevention in hereditary colorectal cancer syndromes.
Chemoprevention of Colonic Polyps with Balsalazide: An Exploratory, Double-Blind, Placebo-Controlled Study.
Chemoprevention of colorectal cancer: dietary and pharmacologic approaches.
Chemoprevention of colorectal neoplasia: advances and controversies (the COX-2 story).
Chemoprevention of colorectal neoplasia: the potential for personalized medicine.
Chemopreventive effects of NSAIDs against colorectal cancer: regulation of apoptosis and mitosis by COX-1 and COX-2.
Chemopreventive Efficacy and Mechanism of Licofelone in a Mouse Lung Tumor Model via Aspiration.
Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.
Chemopreventive Efficacy of the Cyclooxygenase-2 (Cox-2) Inhibitor, Celecoxib, Is Predicted by Adenoma Expression of Cox-2 and 15-PGDH.
Chemoprophylaxis in gastrointestinal tumors.
Chicken Skin Mucosa Surrounding Adult Colorectal Adenomas is a Risk Factor for Carcinogenesis.
Co-Expression of Cox-2, C-Met and beta-catenin in Cells Forming Invasive front of Gallbladder Cancer.
Colon cancer chemoprevention: clinical development of aspirin as a chemopreventive agent.
Colon polyps and cancer.
Colorectal adenoma risk is modified by the interplay between polymorphisms in arachidonic acid pathway genes and fish consumption.
Colorectal cancer and non-steroidal anti-inflammatory drugs.
Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?
Colorectal cancer: chemopreventive role of curcumin and resveratrol.
Colorectal polyposis and immune-based therapies.
Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid.
Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis.
Comparison of biomarker expression between proximal and distal colorectal adenomas: The Tennessee-Indiana Adenoma Recurrence Study.
Comparison of cyclo-oxygenase 2 expression in colorectal serrated adenomas to expression in tubular adenomas and hyperplastic polyps.
Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans 3,4,5,4'-tetramethoxystilbene (DMU-212) on adenoma development in the Apc(Min+) mouse and cyclooxygenase-2 in human-derived colon cancer cells.
Connexin43 is overexpressed in Apc(Min/+)-mice adenomas and colocalises with COX-2 in myofibroblasts.
Consensus on the Prevention, Screening, Early Diagnosis and Treatment of Colorectal Tumors in China: Chinese Society of Gastroenterology, October 14-15, 2011, Shanghai, China.
Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences.
Cooperative effects of matrix metalloproteinase and cyclooxygenase-2 inhibition on intestinal adenoma reduction.
Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors.
Cox-2 and cancer chemoprevention: picking up the pieces.
COX-2 expression in adenoma: an imperfect marker for chemoprevention.
COX-2 expression in sporadic colorectal adenomatous polyps is linked to adenoma characteristics.
COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps.
COX-2 inhibition as a tool to treat and prevent colorectal cancer.
COX-2 inhibition in clinical cancer prevention.
COX-2 inhibitors: a potential target for drug therapy in the management of colorectal cancer.
COX-2, mPGES-1 and EP2 receptor immunohistochemical expression in canine and feline malignant mammary tumours.
Cyclo-oxygenase inhibition in colorectal adenomas and cancer.
Cyclooxygenase 1 and 2 expressions in the human thyroid gland.
Cyclooxygenase 2 is up-regulated and localized to macrophages in the intestine of Min mice.
Cyclooxygenase 2, p53, beta-catenin, and APC protein expression in gastric adenomatous polyps.
Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps.
Cyclooxygenase as a Target for Colorectal Cancer Chemoprevention.
Cyclooxygenase-2 and gastric carcinogenesis.
Cyclooxygenase-2 and Hypoxia-Inducible Factor-1alpha protein expression is related to inflammation, and up-regulated since the early steps of colorectal carcinogenesis.
Cyclooxygenase-2 and inducible nitric oxide synthase expression in thyroid neoplasms and their clinicopathological correlation.
Cyclooxygenase-2 and its role in colorectal cancer development.
Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1-deficient mice.
Cyclooxygenase-2 expression and its relationship with proliferation of colorectal adenomas.
Cyclooxygenase-2 expression and oxidative DNA adducts in murine intestinal adenomas: Modification by dietary curcumin and implications for clinical trials.
Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention.
Cyclooxygenase-2 expression in canine mammary tumors.
Cyclooxygenase-2 expression in colorectal adenomas.
Cyclooxygenase-2 expression in FAP patients carrying germ line MYH mutations.
Cyclooxygenase-2 expression in gastrointestinal stromal tumours.
Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival.
Cyclooxygenase-2 expression in human gastric tubular adenomas and carcinomas; correlation with intratumoral microvessel density and apoptotic index.
Cyclooxygenase-2 expression in human pituitary tumors.
Cyclooxygenase-2 expression in spontaneous intestinal neoplasia of domestic dogs.
Cyclooxygenase-2 expression in thyroid neoplasms.
Cyclooxygenase-2 expression is abundant in alveolar type II cells in lung cancer-sensitive mouse strains and in premalignant lesions.
Cyclooxygenase-2 expression is associated with increased size in human sporadic colorectal adenomas.
Cyclooxygenase-2 expression is related to the epithelial-to-mesenchymal transition in human colon cancers.
Cyclooxygenase-2 immunohistochemical expression in serrated polyps of the colon.
Cyclooxygenase-2 immunoreactivity in depressed-type colorectal adenomas and cancers.
Cyclooxygenase-2 in normal, hyperplastic and neoplastic follicular cells of the human thyroid gland.
Cyclooxygenase-2 in sporadic colorectal polyps: immunohistochemical study and its importance in the early stages of colorectal tumorigenesis.
Cyclooxygenase-2 inhibition in colon experimental carcinogenesis.
Cyclooxygenase-2 is overexpressed in serrated adenoma of the colorectum.
Cyclooxygenase-2 overexpression abrogates the antiproliferative effects of TGF-beta.
Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis.
Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma.
Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial.
Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.
Cyclooxygenase-2: from arthritis treatment to new indications for the prevention and treatment of cancer.
Decreased Toll-interacting protein and peroxisome proliferator-activated receptor ? are associated with increased expression of Toll-like receptors in colon carcinogenesis.
Deletion of the AU-rich RNA binding protein Apobec-1 reduces intestinal tumor burden in Apc(min) mice.
Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention.
Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps.
Diagnostic utility of immunohistochemical panel in various thyroid pathologies.
Differential stromal and epithelial localization of cyclooxygenase-2 (COX-2) during colorectal tumorigenesis.
Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia.
Disruption of cyclooxygenase-1 gene results in an impaired response to radiation injury.
Distinct changes of dendritic cell number and IL-12 mRNA level in adjacent mucosa throughout the colorectal adenoma-carcinoma sequence.
Does a selective cyclooxygenase-2 inhibitor (tiracoxib) induce clinically sufficient suppression of adenomas in patients with familial adenomatous polyposis? A randomized double-blind placebo-controlled clinical trial.
Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke.
E-cadherin expression is homogeneously reduced in adenoma from patients with familial adenomatous polyposis: an immunohistochemical study of E-cadherin, beta-catenin and cyclooxygenase-2 expression.
E1A-F is overexpressed early in human colorectal neoplasia and associated with cyclooxygenase-2 and matrix metalloproteinase-7.
Early expression of cyclo-oxygenase-2 during sporadic colorectal carcinogenesis.
Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.
Effect of prostaglandin E1 on vascular endothelial growth factor production by human macrophages and colon cancer cells.
Effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials.
Elevated cyclooxygenase-2 levels in Min mouse adenomas.
Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon.
Epithelial-Specific Deletion of 11?-HSD2 Hinders Apcmin/+ Mouse Tumorigenesis.
Expression of BMP2, TLR3, TLR4 and COX2 in colorectal polyps, adenoma and adenocarcinoma.
Expression of COX-2 and Wnt pathway genes in adenomas of familial adenomatous polyposis patients treated with meloxicam.
Expression of COX-2, IL-1?, TNF-? and IL-4 in epithelium of serrated adenoma, adenoma and hyperplastic polyp.
Expression of cyclooxygenase-2 (COX-2) mRNA in human colorectal adenomas.
Expression of Cyclooxygenase-2 and Bcl-2 in human gastric adenomas.
Expression of cyclooxygenase-2 and thromboxane synthase in non-neoplastic and neoplastic thyroid lesions.
Expression of cyclooxygenase-2 and vascular endothelial growth factor in pancreatic tumors.
Expression of cyclooxygenase-2 in colonic polyps.
Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas.
Expression of Cyclooxygenase-2 Protein in Gastric Carcinogenesis.
Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial.
G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2.
Gastric adenomas: relationship between clinicopathological findings, Helicobacter pylori infection, APC mutations and COX-2 expression.
Gene-specific methylation and subsequent risk of colorectal adenomas among participants of the polyp prevention trial.
Genetic polymorphisms in the cyclooxygenase-1 and cyclooxygenase-2 genes and risk of colorectal adenoma.
Genetic polymorphisms of cyclooxygenase-2 and colorectal adenoma risk: the Self Defense Forces Health Study.
Genetic variability in prostaglandin synthesis, fish intake and risk of colorectal polyps.
Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors.
Hepatocyte growth factor expression correlates with cyclooxygenase-2 pathway in human salivary gland tumors.
HETEs enhance IL-1-mediated COX-2 expression via augmentation of message stability in human colonic myofibroblasts.
High cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) contents in mouse lung tumors.
High expression of cyclooxygenase-2 in macrophages of human colonic adenoma.
High prevalence of cyclooxygenase 2 expression in papillary thyroid carcinoma.
hMLH1, hMSH2 and cyclooxygenase-2 (cox-2) in sporadic colorectal polyps.
Human colorectal adenomas demonstrate a size-dependent increase in epithelial cyclooxygenase-2 expression.
Immunoexpression of the COX-2, p53, and caspase-3 proteins in colorectal adenoma and non-neoplastic mucosa.
Immunohistochemical analysis and in situ hybridization of cyclooxygenase-2 expression in intraductal papillary-mucinous tumors of the pancreas.
Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors.
Immunohistochemical expression of COX-2 in thyroid nodules.
Immunohistochemical expression of cyclooxygenase (COX)-2 in colorectal adenomas.
Immunohistochemical expression of cyclooxygenase 2 in follicular carcinomas of the thyroid.
Immunohistochemical expressions of Ki-67, cyclin D1, beta-catenin, cyclooxygenase-2, and epidermal growth factor receptor in human colorectal adenoma: a validation study of tissue microarrays.
Immunohistochemical study of cyclooxygenase-2 in skin tumors.
Impact of COX-2, IL-1?, TNF-?, IL-4 and IL-10 on the process of carcinogenesisin the large bowel.
Impact of cyclooxygenase-2 over-expression on the prognosis of colorectal cancer patients. An experience from Western Saudi Arabia.
Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G -> C COX-2 polymorphism.
Increased cyclooxygenase-2 expression in juvenile polyposis syndrome.
Increased EP4 Receptor Expression in Colorectal Cancer Progression Promotes Cell Growth and Anchorage Independence.
Increased expression of cyclooxygenase-2 and Ki-67 are associated with malignant transformation of pleomorphic adenoma.
Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors.
Increased expression of cyclooxygenase-2 in rat lung tumors induced by the tobacco-specific nitrosamine 4-(methylnitrosamino)-4-(3-pyridyl)-1-butanone: the impact of a high-fat diet.
Increased expression of cyclooxygenase-2 protein in rat lung tumors induced by N-nitrosobis(2-hydroxypropyl)amine.
Increased expression of cyclooxygenase-2 to -1 in human colorectal cancers and adenomas, but not in hyperplastic polyps.
Increased expression of cytoplasmic HuR in familial adenomatous polyposis.
Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas.
Increased levels of promutagenic etheno-DNA adducts in colonic polyps of FAP patients.
Indomethacin reduces lung adenoma number in A/J mice.
Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer.
Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans.
Inhibition of apoptosis in normal and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2.
Inhibition of cyclooxygenase-2 causes regression of gastric adenomas in trefoil factor 1 deficient mice.
Interaction of cigarette smoking with cyclooxygenase-2 on ulcerative colitis-associated neoplasia in mice.
Interplay of insulin-like growth factor-II, insulin-like growth factor-I, insulin-like growth factor-I receptor, COX-2, and matrix metalloproteinase-7, play key roles in the early stage of colorectal carcinogenesis.
Interstitial cell cyclooxygenase-2 expression is associated with increased angiogenesis in human sporadic colorectal adenomas.
Intestinal PTGS2 mRNA levels, PTGS2 gene polymorphisms, and colorectal carcinogenesis.
Is COX-2 a 'collateral' target in cancer prevention?
Is there a place for practical chemoprevention of colorectal cancer in light of COX-2 heterogeneity?
Lack of anti-tumor activity with the ?-catenin expression inhibitor EZN-3892 in the C57BL/6J Min/+ model of intestinal carcinogenesis.
Linkage Disequilibrium and Haplotype Analysis of COX-2 and Risk of Colorectal Adenoma Development.
Localization of cyclooxygenase-2 in human sporadic colorectal adenomas.
Molecular analysis of sulindac-resistant adenomas in familial adenomatous polyposis.
Molecular markers of carcinogenesis for risk stratification of individuals with colorectal polyps: a case-control study.
Molecular Pathways and Cellular Metabolism in Colorectal Cancer.
Monocyte chemoattractant protein 1 and macrophage cyclooxygenase 2 expression in colonic adenoma.
Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force.
NSAIDs and colorectal cancer prevention.
NSAIDs and the gastrointestinal tract.
Nuclear factor kappaB is downregulated and correlates with p53 in the Min mouse mucosa during an accelerated tumor growth.
Paracrine cyclooxygenase-2 activity by macrophages drives colorectal adenoma progression in the Apc (Min/+) mouse model of intestinal tumorigenesis.
Paracrine cyclooxygenase-2-mediated signalling by macrophages promotes tumorigenic progression of intestinal epithelial cells.
Pathologic Features of Colorectal Inflammatory Polyps in Miniature Dachshunds.
Persistent cyclooxygenase-2 inhibition downregulates NF-{kappa}B, resulting in chronic intestinal inflammation in the min/+ mouse model of colon tumorigenesis.
Pharmacological and dietary factors in prevention of colorectal cancer.
Piroxicam-induced regression of intestinal adenomatous polyps in APC(delta474) mice.
Polymorphisms in PTGS1, PTGS2 and IL-10 do not influence colorectal adenoma recurrence in the context of a randomized aspirin intervention trial.
Polymorphisms in the genes involved in the arachidonic acid-pathway, fish consumption and the risk of colorectal cancer.
Pomegranate By-Products in Colorectal Cancer Chemoprevention: Effects in Apc-Mutated Pirc Rats and Mechanistic Studies In Vitro and Ex Vivo.
Potential targets for colorectal cancer prevention.
Prevention of colorectal cancer through the use of COX-2 selective inhibitors.
Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications.
Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade.
Prostaglandin-endoperoxide synthase 2 (cyclooxygenase-2), a complex target for colorectal cancer prevention and therapy.
Prostaglandins up-regulate vascular endothelial growth factor production through distinct pathways in differentiated U937 cells.
Protective effect of Cox-2 allelic variants on risk of colorectal adenoma development in African Americans.
Protein expression of Fragile Histidine Triad and cyclooxgenase-2 in serrated neoplasia of the colorectum.
Pterostilbene inhibits colorectal aberrant crypt foci (ACF) and colon carcinogenesis via suppression of multiple signal transduction pathways in azoxymethane-treated mice.
PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs.
Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers.
Reduced tumour progression and angiogenesis in 1,2-dimethylhydrazine mice treated with NS-398 is associated with down-regulation of cyclooxygenase-2 and decreased beta-catenin nuclear localisation.
Regulation of stromal cell cyclooxygenase-2 in the ApcMin/+ mouse model of intestinal tumorigenesis.
Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner.
Relation of the expression of cyclooxygenase-2 in colorectal adenomas and adenocarcinomas to angiogenesis and prognosis.
Relationship between COX-2 expression and clinicopathological features of colorectal cancers.
Relationship between cyclooxygenase-2 expression and K-ras gene mutation in colorectal adenomas.
Reversal of expression of 15-lipoxygenase-1 to cyclooxygenase-2 is associated with development of colonic cancer.
Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor.
Review article: COX-2, prostanoids and colon cancer.
Role of COX-2 in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients' prognosis.
Screening for colon cancer and evaluation of chemoprevention with coxibs.
Size-dependent expression of cyclooxygenase-2 in sporadic colorectal adenomas relative to adenomas in patients with familial adenomatous polyposis.
Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis.
Specific COX-2 inhibitors in arthritis, oncology, and beyond: where is the science headed?
Subepithelial myofibroblasts express cyclooxygenase-2 in colorectal tubular adenomas.
Superficially elevated colonic adenoma changed to undetectable configuration on ordinary endoscopy during treatment with preferential cyclooxygenase-2 inhibitor.
Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
Suppressive effect of sulindac on branch duct-intraductal papillary mucinous neoplasms.
Surveillance colonoscopy or chemoprevention with COX-2 inhibitors in average-risk post-polypectomy patients: a decision analysis.
Synergism between K-rasVal12 and mutant Apc accelerates murine large intestinal tumourigenesis.
Testing for colon neoplasia susceptibility variants at the human COX2 locus.
The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding.
The clinical potential of cyclooxygenase-2-specific inhibitors.
The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence.
The Dynamic Changes of Gut Microbiota in Muc2 Deficient Mice.
The expression and significance of feces cyclooxygensae-2 mRNA in colorectal cancer and colorectal adenomas.
The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis.
The relationship between cyclooxygenase-2 expression and characteristics of malignant transformation in human colorectal adenomas.
The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia.
The role of cyclooxygenase-2 (COX-2) in two different morphological stages of intestinal polyps in APC(Delta474) knockout mice.
The Roles of Dietary PPARgamma Ligands for Metastasis in Colorectal Cancer.
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas.
Up-regulation of cyclooxygenase-2 expression in lymphocytic thyroiditis and thyroid tumors: significant correlation with inducible nitric oxide synthase.
Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction.
WNT and cyclooxygenase-2 cross-talk accelerates adenoma growth.
[Aspirin in the prevention of colorectal cancer.]
[Chemoprevention of colorectal cancer]
[COX-2 inhibitors in inflammatory bowel disease: friends or foes?]
[Cyclo-oxygenase-2 and p53 immunoreactivity in superficial early colorectal carcinoma]
[Cyclooxygenase-2 expression according to size and location of gastric and colorectal tubular adenomas]
[Effects of cyclooxygenase-2 and proliferating cell nuclear antigen on the onset and development of familial adenomatous polyposis]
[Expression of cyclooxygenase-2 and relationship with mismatch repaire gene and microsatellite instability in hereditary non-polyposis colorectal cancer]
[Prevention and early diagnosis of colorectal cancer]
[Prophylaxis of colorectal cancer with non steroidal anti-inflammatory drugs- a new reality?]
[Selective cyclooxygenase-2 inhibitors for the prevention of colorectal adenomas: a meta-analysis]
ß-catenin, Cox-2 and p53 immunostaining in colorectal adenomas to predict recurrence after endoscopic polypectomy.
Adenoma, Oxyphilic
Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors.
Adenoma, Pleomorphic
Abnormal activation of the Akt signaling pathway in adenoid cystic carcinoma.
Cyclooxygenase-2 regulates the degree of apoptosis by modulating bcl-2 protein in pleomorphic adenoma and mucoepidermoid carcinoma of the parotid gland.
Differential expression of cyclooxygenase-2 and cyclin D1 in salivary gland tumors.
Elevated expression of cyclooxygenase-2 in adenocarcinoma of the parotid gland: insights into malignant transformation of pleomorphic adenoma.
Expression of cyclooxygenase-2, Bcl-2 and Ki-67 in pleomorphic adenoma with special reference to tumor proliferation and apoptosis.
Hepatocyte growth factor expression correlates with cyclooxygenase-2 pathway in human salivary gland tumors.
Increased expression of cyclooxygenase-2 and Ki-67 are associated with malignant transformation of pleomorphic adenoma.
Overexpression of cyclooxygenase-2 correlates with cytoplasmic HuR expression in salivary mucoepidermoid carcinoma but not in pleomorphic adenoma.
[Expression and clinical significance of Cox-2 and XIAP in malignant tumors of the salivary gland].
Adenoma, Villous
Analysis of cyclooxygenase expression in human colorectal adenomas.
Prostaglandin E2-mediated secretory diarrhea in villous adenoma of rectum: effect of treatment with indomethacin.
[Treatment with indomethacin for the control of the metabolic disorder caused by a villous adenoma of the rectum]
Adenomatous Polyposis Coli
A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis.
A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients.
Adenomatous polyposis coli protein associates with C/EBP beta and increases Bacillus anthracis edema toxin-stimulated gene expression in macrophages.
An increased CD25-positive intestinal regulatory T-lymphocyte population is dependent on Cox-2 activity in the Apc (Min/+) model.
Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro.
Approach to angiogenesis inhibition based on cyclooxygenase-2.
Association between adenomatosis polyposis coli functional status and microsomal prostaglandin E synthase-1 expression in colorectal cancer.
Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer.
Celecoxib for the prevention of sporadic colorectal adenomas.
Celecoxib induces anoikis in human colon carcinoma cells associated with the deregulation of focal adhesions and nuclear translocation of p130Cas.
Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin.
Celecoxib with chemotherapy in colorectal cancer.
Celecoxib: a new option in the treatment of arthropathies and familial adenomatous polyposis.
Chemoprevention comes to clinical practice: COX-2 inhibition in familial adenomatous polyposis.
Chemoprevention in colorectal neoplasias: what is practical and feasible?
Chemoprevention of colorectal cancer with nonsteroidal anti-inflammatory drugs.
Chemoprevention of colorectal cancer.
Chemoprevention strategies using NSAIDs and COX-2 inhibitors.
Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia.
Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.
Colon cancer chemoprevention: clinical development of aspirin as a chemopreventive agent.
Colon cancer: a civilization disorder.
Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice.
Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice.
Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis.
COX selectivity and animal models for colon cancer.
COX-2 and colon cancer.
COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps.
COX-2 inhibition and colorectal cancer.
COX-2 inhibition and prevention of cancer.
COX-2 inhibition in clinical cancer prevention.
COX-2 polymorphisms in patients with familial adenomatous polyposis.
Current application of selective COX-2 inhibitors in cancer prevention and treatment.
Cyclo-oxygenase 2 inhibitors: emerging roles in the gut.
Cyclo-oxygenase inhibition in colorectal adenomas and cancer.
Cyclooxygenase 2, p53, beta-catenin, and APC protein expression in gastric adenomatous polyps.
Cyclooxygenase 2: a molecular target for cancer prevention and treatment.
Cyclooxygenase 2: from inflammation to carcinogenesis.
Cyclooxygenase inhibitors in the chemoprevention of colorectal cancer.
Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells.
Cyclooxygenase-2 and chemoprevention of breast cancer.
Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis.
Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps.
Cyclooxygenase-2 inhibitors in colorectal cancer.
Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis.
Cyclooxygenases and colon cancer.
Differential expression of matrilysin and cyclooxygenase-2 in intestinal and colorectal neoplasms.
Does a selective cyclooxygenase-2 inhibitor (tiracoxib) induce clinically sufficient suppression of adenomas in patients with familial adenomatous polyposis? A randomized double-blind placebo-controlled clinical trial.
E-cadherin expression is homogeneously reduced in adenoma from patients with familial adenomatous polyposis: an immunohistochemical study of E-cadherin, beta-catenin and cyclooxygenase-2 expression.
Effect of sulindac treatment for attenuated familial adenomatous polyposis with a new germline APC mutation at codon 161: report of a case.
Effects of a selective cyclooxygenase-2 inhibitor on cancer cells in vitro.
Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon.
Enhanced in vitro percutaneous absorption and in vivo anti-inflammatory effect of a selective cyclooxygenase inhibitor using microemulsion.
Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis.
Expression of COX-2 and p53 in juvenile polyposis coli and its correlation with adenomatous changes.
Expression of COX-2 and Wnt pathway genes in adenomas of familial adenomatous polyposis patients treated with meloxicam.
Germline alterations in the cyclooxygenase-2 gene are not associated with the development of extracolonic manifestations in a large swiss familial adenomatous polyposis kindred.
Hereditary nonpolyposis colorectal cancer: preventive management.
Host Wnt/{beta}-catenin pathway triggered by Helicobacter pylori correlates with regression of gastric intestinal metaplasia after H. pylori eradication.
Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G -> C COX-2 polymorphism.
Increased cyclooxygenase-2 expression in juvenile polyposis syndrome.
Increased expression of cytoplasmic HuR in familial adenomatous polyposis.
Inducible heat shock protein 70 prevents multifocal flat dysplastic lesions and invasive tumors in an inflammatory model of colon cancer.
Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.
Is COX-2 a 'collateral' target in cancer prevention?
Label-free global serum proteomic profiling reveals novel celecoxib-modulated proteins in familial adenomatous polyposis patients.
Lack of inducible nitric oxide synthase promotes intestinal tumorigenesis in the Apc(Min/+) mouse.
Molecular pathology of cyclooxygenase-2 in neoplasia.
Mucosal prostanoid receptors and synthesis in familial adenomatous polyposis.
Myofibroblasts. II. Intestinal subepithelial myofibroblasts.
Na(+)-stimulated Na+/H+ exchange and an unfavorable Ca2+ homeostasis initiate the cycloxygenase-2 inhibitors-induced apoptotic signals in colonic epithelial cells during the early stage of colon carcinogenesis.
Nimesulide, a selective anti-inflammatory cyclooxygenase-2 inhibitor, does not affect polyp number and mucosal proliferation in familial adenomatous polyposis.
Non steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics: hypes, hopes and reality.
Oxidative stress in familial adenomatous polyposis.
Potential use of COX-2-aromatase inhibitor combinations in breast cancer.
Prebiotic treatment reduced preneoplastic lesions through the downregulation of toll like receptor 4 in a chemo-induced carcinogenic model.
Prevention of colorectal cancer through the use of COX-2 selective inhibitors.
Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications.
Protective mechanisms of 6-gingerol in dextran sulfate sodium-induced chronic ulcerative colitis in mice.
Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers.
Reduction of intestinal neoplasia with adenomatous polyposis coli gene replacement and COX-2 inhibition is additive.
Regulation of stromal cell cyclooxygenase-2 in the ApcMin/+ mouse model of intestinal tumorigenesis.
Relationship among expression of basic-fibroblast growth factor, MTDH/Astrocyte elevated gene-1, adenomatous polyposis coli, matrix metalloproteinase 9,and COX-2 markers with prognostic factors in prostate carcinomas.
Relationship between Fecal Content of Fatty Acids and Cyclooxygenase mRNA Expression and Fatty Acid Composition in Duodenal Biopsies, Serum Lipoproteins, and Dietary Fat in Colectomized Familial Adenomatous Polyposis Patients.
Retinoic acid inhibits beta-catenin through suppression of Cox-2: a role for truncated adenomatous polyposis coli.
Role of cyclooxygenase-2 in colorectal cancer.
Screening for colon cancer and evaluation of chemoprevention with coxibs.
Selective cyclooxygenase-2 inhibition: a target in cancer prevention and treatment.
Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention.
Size-dependent expression of cyclooxygenase-2 in sporadic colorectal adenomas relative to adenomas in patients with familial adenomatous polyposis.
Studies on the development of colon-targeted delivery systems for celecoxib in the prevention of colorectal cancer.
Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2).
Targeting cyclooxygenase-2 for prevention and therapy of colorectal cancer.
The adenomatous polyposis coli tumor suppressor gene regulates expression of cyclooxygenase-2 by a mechanism that involves retinoic acid.
The anti-proliferative potency of celecoxib is not a class effect of coxibs.
The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
The inducible prostaglandin biosynthetic enzyme, cyclooxygenase 2, is not mutated in patients with attenuated adenomatous polyposis coli.
The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia.
The role of cyclooxygenase-2 (COX-2) in two different morphological stages of intestinal polyps in APC(Delta474) knockout mice.
The role of cyclooxygenase-2 and prostaglandins in colon cancer.
Use of NSAIDs for the chemoprevention of colorectal cancer.
[Chemoprevention of colorectal cancer]
[COX and study of cancer therapy]
[COX inhibitor, suppression of polyposis, and chemoprevention]
[Cyclooxygenase 2 inhibitors and adenomatous polyposis coli]
[Cyclooxygenase-2 expression according to size and location of gastric and colorectal tubular adenomas]
[Effect of celecoxib, a COX-2 inhibitor, in familial adenomatous polyposis]
[Effects of cyclooxygenase-2 and proliferating cell nuclear antigen on the onset and development of familial adenomatous polyposis]
Adenomatous Polyps
Activator protein-1 transcription factor mediates bombesin-stimulated cyclooxygenase-2 expression in intestinal epithelial cells.
Angiotensin II and epidermal growth factor induce cyclooxygenase-2 expression in intestinal epithelial cells through small GTPases using distinct signaling pathways.
Celecoxib Alters the Intestinal Microbiota and Metabolome in Association with Reducing Polyp Burden.
Celecoxib as adjunctive therapy for treatment of colorectal cancer.
Celecoxib for the prevention of colorectal adenomatous polyps.
Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis.
Colorectal Cancer Screening and Prevention.
Colorectal cancer: a summary of the evidence for screening and prevention.
COX-2 and colon cancer: Potential targets for chemoprevention.
COX-2 and colon cancer: potential targets for chemoprevention.
COX-2 expression in sporadic colorectal adenomatous polyps is linked to adenoma characteristics.
COX-derived prostanoid pathways in gastrointestinal cancer development and progression: Novel targets for prevention and intervention.
Cyclooxygenase 2, p53, beta-catenin, and APC protein expression in gastric adenomatous polyps.
hMLH1, hMSH2 and cyclooxygenase-2 (cox-2) in sporadic colorectal polyps.
Homeobox protein CDX2 reduces Cox-2 transcription by inactivating the DNA-binding capacity of nuclear factor-kappaB.
Non-Steroidal Anti-inflammatory Drug Use and Risk of Adenomatous and Hyperplastic Polyps.
Non-steroidal anti-inflammatory drugs and the risk of cardiovascular diseases: are we going to see the revival of cyclooxygenase-2 selective inhibitors?
Prostaglandin E(2) stimulates progression-related gene expression in early colorectal adenoma cells.
Rectal cancer after sulindac therapy for a sporadic adenomatous colonic polyp.
Survey of molecular profiling during human colon cancer development and progression by immunohistochemical staining on tissue microarray.
The relationship between cyclooxygenase-2 expression and characteristics of malignant transformation in human colorectal adenomas.
[Selective cyclooxygenase-2 inhibitors for the prevention of colorectal adenomas: a meta-analysis]
Adenomyosis
Correlation of LOX?5 and COX?2 expression with inflammatory pathology and clinical features of adenomyosis.
Cyclooxygenase-2 (COX-2) expression in human endometrial carcinoma and precursor lesions and its possible use in cancer chemoprevention and therapy.
Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis.
Effect of a hormone-releasing intrauterine system (Mirena(®)) on aromatase and Cox-2 expression in patients with adenomyosis submitted or not, to endometrial resection.
Effect of the menstrual cycle and oral contraceptives on aromatase and cyclooxygenase-2 expression in adenomyosis.
Expression of Cyclooxygenase-2 and Matrix Metalloproteinase-2 in Adenomyosis and Endometrial Polyps and its Correlation With Angiogenesis.
Genetic variation in COX-2 -1195 and the risk of endometriosis and adenomyosis.
Immunohistochemical localization of prostaglandin H synthase in the female reproductive tract and endometriosis.
Leonurine Attenuates Hyperalgesia in Mice with Induced Adenomyosis.
Small primary adenocarcinoma in adenomyosis with nodal metastasis: a case report.
Suppression of migratory/invasive ability and induction of apoptosis in adenomyosis-derived mesenchymal stem cells by cyclooxygenase-2 inhibitors.
The cancer marker neutrophil gelatinase-associated lipocalin is highly expressed in human endometrial hyperplasia.
The effect of oral contraceptives on aromatase and Cox-2 expression in the endometrium of patients with idiopathic menorrhagia or adenomyosis.
Adenosarcoma
Cyclooxygenase-2 expression in malignant mesenchymal tumors and related uterine lesions.
Adenoviridae Infections
The cyclo-oxygenase 2 promoter is induced in nontarget cells following adenovirus infection, but an AU-rich 3'-untranslated region destabilization element can increase specificity.
Adrenoleukodystrophy
Arachidonic acid metabolism in fibroblasts from patients with peroxisomal diseases: response to interleukin 1.
Cyclooxygenase pathway in dermal fibroblasts from patients with metabolic disorders of peroxisomal origin.
African Swine Fever
The viral protein A238L inhibits cyclooxygenase-2 expression through a nuclear factor of activated T cell-dependent transactivation pathway.
Aggressive Periodontitis
Effect of a cyclooxygenase-2 inhibitor on interleukin-1beta-stimulated activation of the transcription factor nuclear factor-kappa B in human gingival fibroblasts.
Airway Obstruction
Airway constriction in normal humans produced by inhalation of leukotriene D. Potency, time course, and effect of aspirin therapy.
Analgesic sensitivity in children with asthma.
Bronchopulmonary actions of 1-(1,2,3,4-tetrahydro-1-naphthylenyl)-1H-imidazole, nitric acid salt (LY150310), a substituted imidazole, in the guinea pig.
Eicosanoids modulate hyperpnea-induced late phase airway obstruction and hyperreactivity in dogs.
Intranasal curcumin ameliorates airway inflammation and obstruction by regulating MAPKinase activation (p38, Erk and JNK) and prostaglandin D2 release in murine model of asthma.
The role of cyclooxygenase products in the acute airway obstruction and airway hyperreactivity of ponies with heaves.
[Expressions of cyclooxygenase-2 and matrix metalloproteinase-2 and airflow obstruction in patients with chronic obstructive pulmonary disease]
Albuminuria
A maladaptive role for EP4 receptors in podocytes.
Albumin-induced podocyte injury and protection are associated with regulation of COX-2.
Altered kidney CYP2C and cyclooxygenase-2 levels are associated with obesity-related albuminuria.
Cardiovascular and renal effects of cyclooxygenase inhibition in transgenic rats harboring mouse renin-2 gene (TGR[mREN2]27).
Influence of the selective COX-2 inhibitor celecoxib on sex differences in blood pressure and albuminuria in spontaneously hypertensive rats.
Interaction of the renin angiotensin and cox systems in the kidney.
Intrarenal Dopamine Inhibits Progression of Diabetic Nephropathy.
PGE2 receptor EP3 inhibits water reabsorption and contributes to polyuria and kidney injury in a streptozotocin-induced mouse model of diabetes.
Podocyte COX-2 exacerbates diabetic nephropathy by increasing podocyte (pro)renin receptor expression.
Puromycin Induces Reversible Proteinuric Injury in Transgenic Mice Expressing Cyclooxygenase-2 in Podocytes.
Renal expression of COX-2, ANG II, and AT1 receptor in remnant kidney: strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory.
RENAL PROTECTIVE EFFECT OF CHRONIC INHIBITION OF COX-2 WITH SC58236 IN STREPTOZOTOCIN-DIABETIC RATS.
Selective cyclooxygenase-2 inhibition impairs glomerular capillary healing in experimental glomerulonephritis.
Alkalosis
Different Placebos, Different Mechanisms, Different Outcomes: Lessons for Clinical Trials.
Multiple Ca(2+)-dependent modulators mediate alkalosis-induced vasodilation in newborn piglet lungs.
Alopecia
Cyclooxygenase-2 overexpression in the skin of transgenic mice results in suppression of tumor development.
Expression of cyclooxygenase isozymes during morphogenesis and cycling of pelage hair follicles in mouse skin: precocious onset of the first catagen phase and alopecia upon cyclooxygenase-2 overexpression.
Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia.
Altitude Sickness
Distinct influence of COX-1 and COX-2 on neuroinflammatory response and associated cognitive deficits during high altitude hypoxia.
The effect of naproxen on acute mountain sickness and vascular responses to hypoxia.
Alveolar Bone Loss
Atorvastatin decreases bone loss, inflammation and oxidative stress in experimental periodontitis.
Comparative evaluation of the efficacy of the cyclooxygenase pathway inhibitor and nitric oxide synthase inhibitor in the reduction of alveolar bone loss in ligature induced periodontitis in rats: An experimental study.
COX-2 inhibition decreases VEGF expression and alveolar bone loss during the progression of experimental periodontitis in rats.
Effect of selective cyclooxygenase-2 inhibition on the development of ligature-induced periodontitis in rats.
Effects of NSAIDs on beagle crevicular cyclooxygenase metabolites and periodontal bone loss.
Effects of Selective Versus Non-Selective COX-2 Inhibition on Experimental Periodontitis.
Evidence for the expression of cyclooxygenase-2 enzyme in periodontitis.
Exenatide and Sitagliptin Decrease Interleukin 1?, Matrix Metalloproteinase 9, and Nitric Oxide Synthase 2 Gene Expression But Does Not Reduce Alveolar Bone Loss in Rats With Periodontitis.
Follicle-stimulating hormone enhances alveolar bone resorption via upregulation of cyclooxygenase-2.
Local administration of Tiludronic Acid downregulates important mediators involved in periodontal tissue destruction in experimental periodontitis in rats.
Orthodontic forces add to nicotine-induced loss of periodontal bone : An in vivo and in vitro study.
Pharmacological topics of bone metabolism: a novel bisphosphonate for the treatment of periodontitis.
Protective effects of etoricoxib, a selective inhibitor of cyclooxygenase-2, in experimental periodontitis in rats.
Role of systemic and local administration of selective inhibitors of cyclo-oxygenase 1 and 2 in an experimental model of periodontal disease in rats.
Selective cyclooxygenase-2 inhibition prevents alveolar bone loss in experimental periodontitis in rats.
Selective cyclooxygenase-2 inhibition prevents bone resorption.
Alzheimer Disease
?9-THC-caused synaptic and memory impairments are mediated through COX-2 signaling.
A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment.
Age-dependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice.
Alterations in behavior, amyloid beta-42, caspase-3, and Cox-2 in mutant PS2 transgenic mouse model of Alzheimer's disease.
Altered expression of COX-2 in subdivisions of the hippocampus during aging and in Alzheimer's disease: the Hisayama Study.
Amyloid beta peptide (25-35) activates protein kinase C leading to cyclooxygenase-2 induction and prostaglandin E2 release in primary midbrain astrocytes.
Amyloid-? Induces Cyclooxygenase-2 and PGE2 Release in Human Astrocytes in NF-? B Dependent Manner.
Anti-aging properties of resveratrol: review and report of a potent new antioxidant skin care formulation.
Anti-inflammatory drugs and their mechanism of action.
Anti-inflammatory drugs, cyclooxygenases and other factors.
Ascorbic acid enhances the inhibitory effect of aspirin on neuronal cyclooxygenase-2-mediated prostaglandin E2 production.
Association of prostaglandin-endoperoxide synthase 2 (PTGS2) polymorphisms and Alzheimer's disease in Chinese.
Association study of COX-2 (PTGS2) -765 G/C promoter polymorphism by pyrosequencing in Sicilian patients with Alzheimer's disease.
Association study of interferon-?, cytosolic phospholipase A2, and cyclooxygenase-2 gene polymorphisms in Alzheimer disease.
Association study of polymorphisms in the cyclooxygenase-2 gene and Alzheimer's disease risk in Chinese.
Brain inflammatory reaction in an animal model of neuronal degeneration and its modulation by an anti-inflammatory drug: implication in Alzheimer's disease.
Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT).
Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations.
Clinical aspects of COX-2 inhibitors.
Clinical potential of cyclo-oxygenase-2 inhibitors.
COX-2 and Alzheimer's disease: potential roles in inflammation and neurodegeneration.
COX-2 inhibitors as adjunctive therapy in schizophrenia.
COX-2 inhibitors--IBC conference. 12-13 April 1999, Coronado, CA, USA.
Cox-2 Plays a Vital Role in the Impaired Anxiety Like Behavior in Colchicine Induced Rat Model of Alzheimer Disease.
Cyclo-oxygenase-2 inhibitors: rationale and therapeutic potential for Alzheimer's disease.
Cyclooxygenase (COX)-1 Activity Precedes the COX-2 Induction in Abeta-Induced Neuroinflammation.
Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology.
Cyclooxygenase (COX)-2 and COX-1 potentiate beta-amyloid peptide generation through mechanisms that involve gamma-secretase activity.
Cyclooxygenase and Alzheimer's disease: implications for preventive initiatives to slow the progression of clinical dementia.
Cyclooxygenase and inflammation in Alzheimer's disease: experimental approaches and clinical interventions.
Cyclooxygenase as a target for the antiamyloidogenic activities of nonsteroidal anti-inflammatory drugs in Alzheimer's disease.
Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain.
Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer's disease model mice.
Cyclooxygenase inhibitors--current status and future prospects.
Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition.
Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology.
Cyclooxygenase-1 in human Alzheimer and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons.
Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease.
Cyclooxygenase-2 and presenilin-1 gene expression induced by interleukin-1beta and amyloid beta 42 peptide is potentiated by hypoxia in primary human neural cells.
Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain.
Cyclooxygenase-2 gene polymorphisms and risk of Alzheimer's disease: A meta-analysis.
Cyclooxygenase-2 Gene Polymorphisms and Risk of Alzheimer's Disease: A Possible Biomoleular Explanation.
Cyclooxygenase-2 in the hippocampus is up-regulated in Alzheimer's disease but not in variant Alzheimer's disease with cotton wool plaques in humans.
Cyclooxygenase-2 Induced the ?-Amyloid Protein Deposition and Neuronal Apoptosis Via Upregulating the Synthesis of Prostaglandin E2 and 15-Deoxy-?12,14-prostaglandin J2.
Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology.
Cyclooxygenase-2 stimulates production of amyloid beta-peptide in neuroblastoma x glioma hybrid NG108-15 cells.
Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors.
Cyclooxygenase-dependent lipid-modification of brain proteins.
Cyclooxygenases 1 and 2.
Cyclooxygenases in the central nervous system: implications for treatment of neurological disorders.
Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern.
Decreased expression of prostaglandin G/H synthase-2 (PGHS-2) in Alzheimer's disease brain.
Defining the role of COX-2 inhibitors in inflammatory and other diseases.
Deletion of microsomal prostaglandin E synthase-1 protects neuronal cells from cytotoxic effects of ?-amyloid peptide fragment 31-35.
Design, Synthesis and In Vitro Study of 5,6-Diaryl-1,2,4-triazine-3-ylthioacetate Derivatives as COX-2 and ?-Amyloid Aggregation Inhibitors.
Detection of Cyclooxygenase-1 in Activated Microglia During Amyloid Plaque Progression: PET Studies in Alzheimer's Disease Model Mice.
Differential effects of cyclooxygenase inhibitors on intracerebroventricular colchicine-induced dysfunction and oxidative stress in rats.
Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs.
Downregulation of neuronal cyclooxygenase-2 expression in end stage Alzheimer's disease.
Drp1-dependent mitochondrial fission regulates p62-mediated autophagy in LPS-induced activated microglial cells.
Effect of acetylcholinesterase inhibitors donepezil and rivastigmine on the activity and expression of cyclooxygenases in a model of the inflammatory action of fluoride on macrophages obtained from THP-1 monocytes.
Eicosanoids Derived From Arachidonic Acid and Their Family Prostaglandins and Cyclooxygenase in Psychiatric Disorders.
Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease.
Evodiamine improves congnitive abilities in SAMP8 and APP(swe)/PS1(?E9) transgenic mouse models of Alzheimer's disease.
Experimental brain inflammation and neurodegeneration as model of Alzheimer's disease: protective effects of selective COX-2 inhibitors.
From epidemiology to therapeutic trials with anti-inflammatory drugs in Alzheimer's disease: the role of NSAIDs and cyclooxygenase in beta-amyloidosis and clinical dementia.
Glial and neuronal expression of cyclooxygenase-2: relevance to Alzheimer's disease.
Imaging of cyclooxygenase-2 (COX-2) expression: potential use in diagnosis and drug evaluation.
Induction of cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma during nitric oxide-induced apoptotic PC12 cell death.
Induction of the complement component C1qB in brain of transgenic mice with neuronal overexpression of human cyclooxygenase-2.
Inflammatory Cyclooxygenase Activity and PGE2 Signaling in Models of Alzheimer's Disease.
Influence of four polymorphisms in ABCA1 and PTGS2 genes on risk of Alzheimer's disease: a meta-analysis.
Inhibition of cyclooxygenase as potential novel therapeutic strategy in N141I presenilin-2 familial Alzheimer's disease.
Integrated communications between cyclooxygenase-2 and Alzheimer's disease.
Interleukin-1beta induced cyclooxygenase 2 expression and prostaglandin E2 secretion by human neuroblastoma cells: implications for Alzheimer's disease.
Interleukin-1beta induces cyclooxygenase-2 and prostaglandin E(2) synthesis in human neuroblastoma cells: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB.
Is there a Future for Cyclo-Oxygenase Inhibitors in Alzheimer's Disease?
Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease.
Long non-coding RNA MALAT1 Inhibits Neuron Apoptosis and Neuroinflammation while Stimulates Neurite Outgrowth and its Correlation with MiR-125b Mediated PTGS2, CDK5 and FOXQ1 in Alzheimer's Disease.
Long-term efficacy and safety of celecoxib in Alzheimer's disease.
Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease.
Maximal COX-2 and ppRb expression in neurons occurs during early Braak stages prior to the maximal activation of astrocytes and microglia in Alzheimer's disease.
Mechanism of action of antiinflammatory drugs.
Mechanisms of prostaglandin E2-induced interleukin-6 release in astrocytes: possible involvement of EP4-like receptors, p38 mitogen-activated protein kinase and protein kinase C.
Mefenamic acid shows neuroprotective effects and improves cognitive impairment in in vitro and in vivo Alzheimer's disease models.
Meta-analysis of cyclooxygenase-2 (COX-2) 765G>C polymorphism and Alzheimer's disease.
Microsomal prostaglandin E synthase-1 is induced in alzheimer's disease and its deletion mitigates alzheimer's disease-like pathology in a mouse model.
Microsomal prostaglandin E synthase-2: Cellular distribution and expression in Alzheimer's disease.
miR-103 Promotes Neurite Outgrowth and Suppresses Cells Apoptosis by Targeting Prostaglandin-Endoperoxide Synthase 2 in Cellular Models of Alzheimer's Disease.
Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease.
Naringin and Rutin Alleviates Episodic Memory Deficits in Two Differentially Challenged Object Recognition Tasks.
Neuroinflammation in Alzheimer's Disease: Are NSAIDs and Selective COX-2 Inhibitors the Next Line of Therapy?
Neuroinflammation in Alzheimer's disease: are NSAIDs and selective COX-2 inhibitors the next line of therapy?
Neuronal COX-2 expression and phosphorylation of pRb precede p38 MAPK activation and neurofibrillary changes in AD temporal cortex.
Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease.
Neuronal expression of cyclooxygenase-2, a pro-inflammatory protein, in the hippocampus of patients with schizophrenia.
Neuroprotective Effect of Cyclooxygenase Inhibitors in ICV-STZ Induced Sporadic Alzheimer's Disease in Rats.
New insights into COX-2 biology and inhibition.
Non-steroidal anti-inflammatory drugs and cyclooxygenase in Alzheimer's disease.
Nonsteroidal antiinflammatory agents.
Novel insights and therapeutical applications in the field of inhibitors of COX-2.
Novel non-steroidal anti-inflammatory drugs: what we have learned from animal studies.
Pain management and beyond: evolving concepts and treatments involving cyclooxygenase inhibition.
Pathophysiological Roles of Cyclooxygenases and Prostaglandins in the Central Nervous System.
Peripheral inflammatory biomarkers of Alzheimer's disease: the role of platelets.
Peroxidase activity of cyclooxygenase-2 (COX-2) cross-links beta-amyloid (Abeta) and generates Abeta-COX-2 hetero-oligomers that are increased in Alzheimer's disease.
Phospholipase A2 is involved in muscarinic receptor-mediated sAPPalpha release independently of cyclooxygenase or lypoxygenase activity in SH-SY5Y cells.
Physicochemical, Stress Degradation Evaluation and Pharmacokinetic Study of AZGH102, a New Synthesized COX2 Inhibitors after I.V. and Oral Administration in Male and Female Rats.
Progress in COX-2 inhibitors: a journey so far.
Prostaglandin G/H synthase-2 (cyclooxygenase-2) mRNA expression is decreased in Alzheimer's disease.
Prostaglandin H2 (PGH2) accelerates formation of amyloid beta1-42 oligomers.
Prostaglandin I
Prostaglandin I2 Attenuates Prostaglandin E2-Stimulated Expression of Interferon ? in a ?-Amyloid Protein- and NF-?B-Dependent Mechanism.
Prostaglandin I2 upregulates the expression of anterior pharynx-defective-1? and anterior pharynx-defective-1? in amyloid precursor protein/presenilin 1 transgenic mice.
Prostaglandin J2: a potential target for halting inflammation-induced neurodegeneration.
Prostaglandins and other lipid mediators in Alzheimer's disease.
Protective effect of non-selective and selective COX-2-inhibitors in acute immobilization stress-induced behavioral and biochemical alterations.
Protective effects of gingerol on streptozotocin-induced sporadic Alzheimer's disease: emphasis on inhibition of ?-amyloid, COX-2, alpha-, beta - secretases and APH1a.
Psychotropic effects of COX-2 inhibitors--a possible new approach for the treatment of psychiatric disorders.
Pyrosequencing of polymorphisms in the COX-2 gene (PTGS2) with reported clinical relevance.
Radiotracers for Molecular Imaging of Cyclooxygenase-2 (COX-2) Enzyme.
Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice.
Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease.
Regulation of APP synthesis and secretion by neuroimmunophilin ligands and cyclooxygenase inhibitors.
Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects.
Role of COX-2 in inflammatory and degenerative brain diseases.
Role of cox-2 mediated neuroinflammation on the neurodegeneration and cognitive impairments in colchicine induced rat model of Alzheimer's Disease.
Role of cyclooxygenase-1 and -2 in health and disease.
Role of Cyclooxygenase-2 and 5-Lipoxygenase Polymorphisms in Alzheimer's Disease in a Population from Northern Italy: Implication for Pharmacogenomics.
Role of cyclooxygenase-2 and 5-lipoxygenase polymorphisms in Alzheimer's disease in a population from northern Italy: implication for pharmacogenomics.
Selective cyclooxygenase-2 inhibitors: pharmacology, clinical effects and therapeutic potential.
Sorafenib inhibits nuclear factor kappa B, decreases inducible nitric oxide synthase and cyclooxygenase-2 expression, and restores working memory in APPswe mice.
Specific COX-2 inhibitors in arthritis, oncology, and beyond: where is the science headed?
Strong nuclear factor-kappaB-DNA binding parallels cyclooxygenase-2 gene transcription in aging and in sporadic Alzheimer's disease superior temporal lobe neocortex.
Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.
Synthesis and in vivo evaluation of 18F-desbromo-DuP-697 as a PET tracer for cyclooxygenase-2 expression.
Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase.
The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding.
The clinical potential of cyclooxygenase-2-specific inhibitors.
The cyclooxygenase 2 -765 C promoter allele is a protective factor for Alzheimer's disease.
The potential application of cyclo-oxygenase type 2 inhibitors to Alzheimer's disease.
The role of COX-1 and COX-2 in Alzheimer's disease pathology and the therapeutic potentials of non-steroidal anti-inflammatory drugs.
The role of inflammation in CNS injury and disease.
The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammation and protects cholinergic neurons from excitotoxic degeneration in vivo.
Thinking outside the box about COX-1 in Alzheimer's disease.
[Clinical application of cyclooxygenase-2 inhibitors]
[Coxibs: highly selective cyclooxygenase-2 inhibitors. Part I. Clinical efficacy]
[Effects of Valeriana amurensis on the expressions of iNOS, COX-2 and IkappaCB-alpha in Alzheimer's disease model rat's brain]
[Non-steroidal anti-inflammatory agents with selective inhibitory activity on cyclooxygenase-2. Interest and future prospects]
[Non-steroidal anti-inflammatory drugs with selectivity for cyclooxygenase-2 in Alzheimer's disease. Rationale and perspectives]
Ameloblastoma
Comparison of fatty acid synthase and cyclooxygenase-2 immunoexpression in embryonal, benign, and malignant odontogenic tissues.
COX-2 as a determinant of lower disease-free survival for patients affected by ameloblastoma.
Immunohistochemical analysis of COX-2 expression in dentigerous cyst, keratocystic odontogenic tumor and ameloblastoma: A comparative study.
Odontogenic epithelial proliferation is correlated with COX-2 expression in dentigerous cyst and ameloblastoma.
Amnesia
Celecoxib as an in vivo probe of cyclooxygenase-2 mechanisms underlying retrograde amnesia in an animal model of ECT.
Possible glutamatergic and lipid signalling mechanisms in ECT-induced retrograde amnesia: experimental evidence for involvement of COX-2, and review of literature.
The IkappaB kinase inhibitor sulfasalazine impairs long-term memory in the crab Chasmagnathus.
The role of the New Zealand Intensive Medicines Monitoring Programme in identification of previously unrecognised signals of adverse drug reactions.
Amnesia, Retrograde
Celecoxib as an in vivo probe of cyclooxygenase-2 mechanisms underlying retrograde amnesia in an animal model of ECT.
Possible glutamatergic and lipid signalling mechanisms in ECT-induced retrograde amnesia: experimental evidence for involvement of COX-2, and review of literature.
Amyloidosis
Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology.
Effect of indomethacin and selective cyclooxygenase-2 inhibitors on proteinuria and renal function in patients with AA type renal amyloidosis.
Induction of cyclooxygenase-2 in human synovial cells by beta 2-microglobulin.
Amyotrophic Lateral Sclerosis
A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis.
Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis.
Altered Lipid Metabolism in Brain Injury and Disorders.
Altered lipid metabolism in brain injury and disorders.
COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord.
Expression and localization of cyclooxygenase-1 and -2 in human sporadic amyotrophic lateral sclerosis.
Function of COX-2 and prostaglandins in neurological disease.
Increased expression of neuronal cyclooxygenase-2 in the hippocampus in amyotrophic lateral sclerosis both with and without dementia.
Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis.
Induction of cyclooxygenase-2 in reactive glial cells by the CD40 pathway: relevance to amyotrophic lateral sclerosis.
Inhibition of cyclooxygenase-2 protects motor neurons in an organotypic model of amyotrophic lateral sclerosis.
Integrative role of cPLA with COX-2 and the effect of non-steriodal anti-inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis.
Is prostaglandin E(2) a pathogenic factor in amyotrophic lateral sclerosis?
Nonsteroidal anti-inflammatory drugs differentially affect the heat shock response in cultured spinal cord cells.
Pathophysiological Roles of Cyclooxygenases and Prostaglandins in the Central Nervous System.
Trial of celecoxib in amyotrophic lateral sclerosis.
Anaphylaxis
Analgesics, allergy and asthma.
Anaphylactic and anaphylactoid reactions to aspirin and other NSAIDs.
Anaphylactoid reaction to a cyclooxygenase-2 inhibitor in a patient who had a reaction to a cyclooxygenase-1 inhibitor.
Anaphylatoxin C3a enhances mucous glycoprotein release from human airways in vitro.
Anti-inflammatory activity of hexane extracts from bones and internal organs of Anguilla japonica suppresses cyclooxygenase-2-dependent prostaglandin D? generation in mast cells and anaphylaxis in mice.
Aspirin and NSAID sensitivity.
Biphasic response of cutaneous blood flow induced by passive cutaneous anaphylaxis in rats.
Bronchial anaphylaxis in actively sensitized Sprague Dawley rats: studies on mediators involved.
Challenge-based clinical patterns of 223 Spanish patients with nonsteroidal anti-inflammatory-drug-induced-reactions.
Ciliary responsiveness in allergic and nonallergic airways.
Cyclooxygenase blockade elevates leukotriene E4 production during acute anaphylaxis in sheep.
Cyclooxygenase metabolites in human lung anaphylaxis: airway vs. parenchyma.
Differential effects of a series of hydroxamic acid derivatives on 5-lipoxygenase and cyclooxygenase from neutrophils and 12-lipoxygenase from platelets and their in vivo effects on inflammation and anaphylaxis.
Effect of C3a and C5a anaphylatoxins on guinea-pig isolated blood vessels.
Effect of pharmacologic agents on antigen-induced decreases in specific lung conductance in sheep.
Effects of 5-lipoxygenase inhibition on cardiac anaphylaxis in isolated guinea pig hearts.
Effects of anaphylaxis mediators on partitioned pulmonary vascular resistance during ragweed shock in dogs.
Effects of exogenous prostaglandins on the release of leukotriene C4-like immunoreactivity and on coronary flow in indomethacin-treated anaphylactic guinea-pig hearts.
Eicosanoid modulation of stress fibers in cultured bovine aortic endothelial cells.
Enhancement of plasma levels of biologically active leukotriene B compounds during anaphylaxis in guinea pigs pretreated by indomethacin or by a fish oil-enriched diet.
Histamine H3 receptor blockade improves cardiac function in canine anaphylaxis.
Idiosyncrasy to pyrazolone drugs.
Involvement of leukotrienes in allergic inflammation in mice.
Leukotrienes, thromboxane A2, and prostaglandins during systemic anaphylaxis in sheep.
Mechanisms of response to antigen in isolated guinea pig trachea after active sensitization.
Meloxicam-associated anaphylactic reaction.
MicroRNA-26a/-26b-COX-2-MIP-2 Loop Regulates Allergic Inflammation and Allergic Inflammation-promoted Enhanced Tumorigenic and Metastatic Potential of Cancer Cells.
Nitric oxide and ?2-adrenoceptor activation attenuate pulmonary vasoconstriction during anaphylactic hypotension in anesthetized BALB/c mice.
Nonsteroidal anti-inflammatory drugs enhance IgE-mediated activation of human basophils in patients with food anaphylaxis dependent and independent of nonsteroidal anti-inflammatory drugs.
On the structure of slow reacting substance of anaphylaxis: evidence of biosynthesis from arachidonic acid.
Ozone-induced bronchial hyperreactivity in guinea pigs is abolished by BW 755C or FPL 55712 but not by indomethacin.
Quantitative analysis of prostanoids in biological fluids by combined capillary column gas chromatography negative ion chemical ionization mass spectrometry.
Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs.
SRS-A mediated bronchospasm by pharmacologic modification of lung anaphylaxis in vivo.
Total profiling by GC/NICIMS of the major cyclo-oxygenase products from antigen and leukotriene-challenged guinea-pig lung.
[Mastocytosis: an important differential diagnosis in anaphylactoid reaction to Hymenoptera sting. A case report and overview of clinical aspects, diagnosis and current therapy of mastocytosis]
Anaplasia
Association between Degree of Anaplasia and Degree of Inflammation with the Expression of COX-2 in Feline Injection Site Sarcomas.
Anemia
Clinical implications of COX-1 and/or COX-2 inhibition for the distal gastrointestinal tract.
Cyclooxygenase-2 is essential for normal recovery from 5-fluorouracil-induced myelotoxicity in mice.
Effect of Exercise on Cardiac Tissue Oxidative and Inflammatory Mediators in Chronic Kidney Disease.
Effect of the misoprostol-rebamipide combination on iron deficiency anemia in patients under long-term cyclooxygenase-2 selective inhibitor treatment for small bowel ulcers.
Effects of cyclooxygenase inhibitors on parasite burden, anemia and oxidative stress in murine Trypanosoma cruzi infection.
Impaired systemic production of prostaglandin E2 in children with cerebral malaria.
Prevention of iron deficiency anemia in IUD users by prostaglandin synthetase inhibitors.
Reduced systemic bicyclo-prostaglandin-E2 and cyclooxygenase-2 gene expression are associated with inefficient erythropoiesis and enhanced uptake of monocytic hemozoin in children with severe malarial anemia.
Suppressed circulating bicyclo-PGE2 levels and leukocyte COX-2 transcripts in children co-infected with P. falciparum malaria and HIV-1 or bacteremia.
[Expression of COX-1 and COX-2 in the Platelet of Iron Deficiency Anemia Women at Childbearing Age and Its Clinical Significance].
Anemia, Hemolytic
Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice.
Anemia, Iron-Deficiency
Effect of the misoprostol-rebamipide combination on iron deficiency anemia in patients under long-term cyclooxygenase-2 selective inhibitor treatment for small bowel ulcers.
Prevention of iron deficiency anemia in IUD users by prostaglandin synthetase inhibitors.
[Expression of COX-1 and COX-2 in the Platelet of Iron Deficiency Anemia Women at Childbearing Age and Its Clinical Significance].
Anemia, Sickle Cell
Micro-MRI methods to detect renal cysts in mice.
Modulation of redox pathways in neutrophils from sickle cell disease patients.
Aneurysm
Differential Sex Response to Aspirin in Decreasing Aneurysm Rupture in Humans and Mice.
Indomethacin inhibits expansion of experimental aortic aneurysms via inhibition of the cox2 isoform of cyclooxygenase.
MF-tricyclic inhibits growth of experimental abdominal aortic aneurysms.
Microsomal Prostaglandin E Synthase-1 Expression by Aortic Smooth Muscle Cells Attenuates the Differentiated Phenotype.
mRNA expression of genes involved in lipid efflux and matrix degradation in occlusive and ectatic atherosclerotic disease.
Oral Presentations of the 2016 Annual Meeting of the Congress of Neurological Surgeons: San Diego, California: September 24-28, 2016: 100?Differential Sex Response to Aspirin in Decreasing Aneurysm Rupture in Humans and Mice.
Protective Effect of Mesenchymal Stem Cells Against the Development of Intracranial Aneurysm Rupture in Mice.
Sp1 increases expression of cyclooxygenase-2 in hypoxic vascular endothelium. Implications for the mechanisms of aortic aneurysm and heart failure.
Suppression of experimental aortic aneurysms: comparison of inducible nitric oxide synthase and cyclooxygenase inhibitors.
Angina, Stable
Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease.
[?ptimization of stable angina standard therapy in patients with concomitant osteoarthritis and obesity].
Angina, Unstable
Altered intraplatelet arachidonic acid metabolism during the acute state of unstable angina.
Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease.
Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses.
Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina.
Effect of early statin and selective cyclooxygenase-2 inhibitor therapy on C-reactive protein level after percutaneous coronary angioplasty in unstable angina.
Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study.
Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease.
High-dose statin and COX-2 inhibitor therapy rapidly decreases C-reactive protein level in patients with unstable angina.
How to get from antiplatelet to antithrombotic treatment.
Identification of differentially expressed genes in coronary atherosclerotic plaques from patients with stable or unstable angina by cDNA array analysis.
Platelet arachidonic acid metabolism in patients with cardiovascular disorders.
Transcellular formation of thromboxane A(2) in mixed incubations of endothelial cells and aspirin-treated platelets strongly depends on the prostaglandin I-synthase activity.
Angioedema
Angioedema associated with aspirin and rofecoxib.
Cutaneous reactions to aspirin and nonsteroidal antiinflammatory drugs.
Management of patients with nonaspirin-exacerbated respiratory disease aspirin hypersensitivity reactions.
NSAID-induced urticaria and angioedema: a reappraisal of its clinical management.
Response to a selective COX-2 inhibitor in patients with urticaria/angioedema induced by nonsteroidal anti-inflammatory drugs.
Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema.
Safety of selective cyclooxygenase-2 inhibitors and a basic non-steroidal anti-inflammatory drug (NSAID) in Japanese patients with NSAID-induced urticaria and/or angioedema: Comparison of meloxicam, etodolac and tiaramide.
Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions.
Urticaria and angioedema from cyclooxygenase-2 inhibitors.
Urticaria and angioedema induced by COX-2 inhibitors.
Anhedonia
Sex-Dependent Effects of Neonatal Inflammation on Adult Inflammatory Markers and Behavior.
Anthrax
Rapid induction of inflammatory lipid mediators by the inflammasome in vivo.
Anti-Glomerular Basement Membrane Disease
Hyaluronan-induced cyclooxygenase-2 expression promotes thromboxane A2 production by renal cells.
Anuria
COX-2 inhibitor induced anuric renal failure in a previously healthy young woman.
Oligohydramnios and transient neonatal anuria: a possible association with the maternal use of prostaglandin synthetase inhibitors.
Aortic Aneurysm
Coexpression of cyclooxygenase-2 and matrix metalloproteinases in human aortic atherosclerotic lesions.
Indomethacin inhibits expansion of experimental aortic aneurysms via inhibition of the cox2 isoform of cyclooxygenase.
Indomethacin Prevents the Progression of Thoracic Aortic Aneurysm in Marfan Syndrome Mice.
Sp1 increases expression of cyclooxygenase-2 in hypoxic vascular endothelium. Implications for the mechanisms of aortic aneurysm and heart failure.
Suppression of experimental aortic aneurysms: comparison of inducible nitric oxide synthase and cyclooxygenase inhibitors.
Aortic Aneurysm, Abdominal
Cyclooxygenase-2 expression and its association with increased angiogenesis in human abdominal aortic aneurysms.
Cyclooxygenase-2 inhibition attenuates abdominal aortic aneurysm progression in hyperlipidemic mice.
Defective p27 phosphorylation at serine 10 affects vascular reactivity and increases abdominal aortic aneurysm development via Cox-2 activation.
Effectiveness of Cyclooxygenase-2 Inhibition in Limiting Abdominal Aortic Aneurysm Progression in Mice Correlates with a Differentiated Smooth Muscle Cell Phenotype.
Genetic deficiency of cyclooxygenase-2 attenuates abdominal aortic aneurysm formation in mice.
Microsomal Prostaglandin E Synthase-1 Expression by Aortic Smooth Muscle Cells Attenuates the Differentiated Phenotype.
mRNA expression of genes involved in lipid efflux and matrix degradation in occlusive and ectatic atherosclerotic disease.
Prostaglandin E2 synthesis and cyclooxygenase expression in abdominal aortic aneurysms.
Regulatory T cells protected against abdominal aortic aneurysm by suppression of the COX-2 expression.
Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice.
The Influence of COX-2 Single Nucleotide Polymorphisms on Abdominal Aortic Aneurysm Development and the Associated Inflammation.
Aortic Coarctation
Increased renal vasoconstriction and gene expression of cyclooxygenase-1 in renovascular hypertension.
Vascular responsiveness to nitric oxide synthesis inhibition in hypertensive rats.
Apnea
A reexamination of the role of oxygen in retrolental fibroplasia.
Role of TRPA1 and TRPV1 in the ROS-dependent sensory irritation of superior laryngeal capsaicin-sensitive afferents by cigarette smoke in anesthetized rats.
Appendiceal Neoplasms
Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis.
Arrhythmias, Cardiac
Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials.
[Further definition of the role of COX-2 inhibitors and NSAIDs in patients with nociceptive pain]
Arteriosclerosis
COX-2-derived prostacyclin modulates vascular remodeling.
PKC-delta/c-Src-mediated EGF receptor transactivation regulates thrombin-induced COX-2 expression and PGE(2) production in rat vascular smooth muscle cells.
Sphingosine-1-phosphate induces COX-2 expression via PI3K/Akt and p42/p44 MAPK pathways in rat vascular smooth muscle cells.
Tissue-specific modulation of cyclooxygenase-2 (Cox-2) expression in the uterus and the v. cava by estrogens and phytoestrogens.
[Further definition of the role of COX-2 inhibitors and NSAIDs in patients with nociceptive pain]
Arteritis
Cytokine expression in temporal arteries: comparative analysis between patients with biopsy-positive giant cell arteritis, biopsy-negative giant cell arteritis and biopsy-negative without arteritis.
Arthralgia
A randomized double blind comparison of short-term duodenally administrated whale and seal blubber oils in patients with inflammatory bowel disease and joint pain.
Alteration of gait parameters in a mouse model of surgically induced knee osteoarthritis.
Cost-effectiveness analysis for joint pain treatment in patients with osteoarthritis treated at the Instituto Mexicano del Seguro Social (IMSS): Comparison of nonsteroidal anti-inflammatory drugs (NSAIDs) vs. cyclooxygenase-2 selective inhibitors.
Cyclooxygenase-2 in synovial tissue and fluid of dysfunctional temporomandibular joints with internal derangement.
Effects of celecoxib on ionic currents and spontaneous firing in rat retinal neurons.
Expression of microRNAs in the plasma of patients with acute gouty arthritis and the effects of colchicine and etoricoxib on the differential expression of microRNAs.
Immunohistochemical localization of cyclooxygenase-1 and -2 in synovial tissues from patients with internal derangement or osteoarthritis of the temporomandibular joint.
In patients with temporomandibular disorders, do particular interventions influence oral health-related quality of life? A qualitative systematic review of the literature.
Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac.
Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer.
Taxanes and COX-2 inhibitors: from molecular pathways to clinical practice.
Arthritis
1,2-Diarylcyclopentenes as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents.
2-hydroxymethyl-4-[5-(4-methoxyphenyl)-3-trifluoromethyl-1H-1-pyrazolyl]-1-benzenesulfonamide (DRF-4367): an orally active COX-2 inhibitor identified through pharmacophoric modulation.
A case of acute liver failure due to etodolac.
A cross-sectional retrospective assessment of anti-arthritic drugs in patients with arthritis in Korea.
A deficiency in the prostaglandin D2 receptor CRTH2 exacerbates adjuvant-induced joint inflammation.
A new ditriazine inhibitor of NF-kappaB modulates chronic inflammation and angiogenesis.
A selective COX-2 inhibitor, meloxicam, as a treatment option in patients with juvenile idiopathic arthritis and gastrointestinal side effects from naproxen.
ABT-963 [2-(3,4-difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], a highly potent and selective disubstituted pyridazinone cyclooxgenase-2 inhibitor.
Accounting for the increase in NSAID expenditure: substitution or leakage?
An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference.
An in vitro screening assay for inhibitors of proinflammatory mediators in herbal extracts using human synoviocyte cultures.
Anti-inflammatory effect and low ulcerogenic activity of etodolac, a cyclooxygenase-2 selective non-steroidal anti-inflammatory drug, on adjuvant-induced arthritis in rats.
Anti-inflammatory Potential of Alpha-Linolenic Acid Mediated Through Selective COX Inhibition: Computational and Experimental Data.
Anti-rheumatoid arthritis effects in adjuvant-induced arthritis in rats and molecular docking studies of Polygonum orientale L. extracts.
Antiinflammatory and analgesic efficacy of COX-2 specific inhibition: from investigational trials to clinical experience.
Antithrombotic and platelet function inhibiting effects of ML3000, a new antiinflammatory drug with Cox/5-LOX inhibitory activity.
Are preferences for cyclooxygenase-2 inhibitors influenced by the certainty effect?
Arthritis develops but fails to resolve during inhibition of cyclooxygenase 2 in a murine model of Lyme disease.
Arthritis suppressor genes TIA-1 and TTP dampen the expression of tumor necrosis factor alpha, cyclooxygenase 2, and inflammatory arthritis.
Articular inflammation induced by an enzymatically-inactive Lys49 phospholipase A
Assessing the cost-effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration.
Bacopa monniera (L.) wettst inhibits type ii collagen-induced arthritis in rats.
Basic biology and clinical application of specific cyclooxygenase-2 inhibitors.
Blood Pressure and Cardiovascular Outcomes in Patients Taking Nonsteroidal Antiinflammatory Drugs.
Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies.
Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade: results of case control studies.
Cardiovascular effects of selective cyclooxygenase-2 inhibitors.
Cardiovascular effects of the selective cyclooxygenase-2 inhibitors.
Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations.
Cardiovascular risk and COX-2 inhibition in rheumatological practice.
Cardiovascular risk, hypertension, and NSAIDs.
Cardiovascular risks of cyclooxygenase-2 inhibitors and traditional anti-inflammatory drugs: necessary but not sufficient for clinical decision making.
Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib.
Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs.
Celecoxib Enhances the Anti-inflammatory Effects of Farnesylthiosalicylic Acid on T Cells Independent of Prostaglandin E(2) Production.
Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.
Celecoxib with chemotherapy in colorectal cancer.
Celecoxib-induced erythema multiforme with glyburide cross-reactivity.
Changes in antitumor response in C57BL/6J-Min/+ mice during long-term administration of a selective cyclooxygenase-2 inhibitor.
Clinical experience with specific COX-2 inhibitors in arthritis.
Clinical implications of selective cyclooxygenase-2 inhibition.
Cloning, expression, and up-regulation of inducible rat prostaglandin e synthase during lipopolysaccharide-induced pyresis and adjuvant-induced arthritis.
Colonic delivery of celecoxib is a potential pharmaceutical strategy for repositioning the selective COX-2 inhibitor as an anti-colitic agent.
Combination therapies that inhibit cyclooxygenase-2 and leukotriene synthesis prevent disease in murine collagen induced arthritis.
Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis.
Comparison of benefit-risk preferences of patients and physicians regarding cyclooxygenase-2 inhibitors using discrete choice experiments.
Comparison of the effects of firocoxib, carprofen and vedaprofen in a sodium urate crystal induced synovitis model of arthritis in dogs.
Complexes of Indomethacin with 4-Carbomethoxy-pyrrolidone PAMAM Dendrimers Show Improved Anti-inflammatory Properties and Temperature-Dependent Binding and Release Profile.
Compositions for treatment of cancer and inflammation.
Computer aided drug design approaches to develop cyclooxygenase based novel anti-inflammatory and anti-cancer drugs.
Contrasting Effects of n-3 and n-6 Fatty Acids on Cyclooxygenase-2 in Model Systems for Arthritis.
Cost-effectiveness of cyclooxygenase-2 inhibitors in chronic arthritis.
COX-1 and COX-2 tissue expression: implications and predictions.
COX-2 in synovial tissues.
COX-2 inhibition and pain management: a review summary.
COX-2 inhibitors. New medication for arthritis pain.
COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
COX-2 selective nonsteroidal anti-Inflammatory drugs: do they really offer any advantages?
COX-2 selective NSAID decreases bone ingrowth in vivo.
COX-2 specific inhibitors in the management of arthritis and pain. Introduction.
COX-2-selective inhibitors in the treatment of arthritis.
COX-2: separating myth from reality.
CT20126, a novel immunosuppressant, prevents collagen-induced arthritis through the down-regulation of inflammatory gene expression by inhibiting NF-kappaB activation.
Current state of therapy for pain and inflammation.
Cyclooxygenase 2 activity modulates the severity of murine Lyme arthritis.
Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.
Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention.
Cyclooxygenase-2 and chemoprevention of breast cancer.
Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma.
Cyclooxygenase-2 in the spinal cord: localization and regulation after a peripheral inflammatory stimulus.
Cyclooxygenase-2 inhibition reverts the decrease in adiponectin levels and attenuates the loss of white adipose tissue during chronic inflammation.
Cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory drugs in the management of arthritis.
Cyclooxygenase-2 inhibitors as a therapeutic target in inflammatory diseases.
Cyclooxygenase-2 inhibitors in lung cancer.
Cyclooxygenase-2 inhibitors: a new approach to the therapy of ocular inflammation.
Cyclooxygenase-2 inhibitors: what went wrong?
Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Cyclooxygenase-2--10 years later.
Cyclooxygenase-2: from arthritis treatment to new indications for the prevention and treatment of cancer.
Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors.
Detection of COX-1 and COX-2 isoforms in synovial fluid cells from inflammatory joint diseases.
Detection of Overexpressed COX-2 in Precancerous Lesions of Hamster Pancreas and Lungs by Molecular Imaging: Implications for Early Diagnosis and Prevention.
Determination of two COX-2 inhibitors in serum and synovial fluid of patients with inflammatory arthritis by ultra performance liquid chromatography-inductively coupled plasma mass spectroscopy and quadrupole time-of-flight mass spectrometry.
Development and clinical application of COX-2-selective inhibitors for the treatment of osteoarthritis and rheumatoid arthritis.
Differential expression of COX-2 in osteoarthritis and rheumatoid arthritis.
Effect of celecoxib, a cyclooxygenase-2 inhibitor, on the pathophysiology of adjuvant arthritis in rat.
Effect of cyclooxygenase inhibition on cholesterol efflux proteins and atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk.
Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study.
Effect of selective COX-2 inhibitor, celecoxib on adjuvant-induced arthritis model in irradiated rats.
Effects of anti-arthritis preparations on gene expression and enzyme activity of cyclooxygenase-2 in cultured equine chondrocytes.
Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis.
Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors.
Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.
Effects of triptolide from Radix Tripterygium wilfordii (Leigongteng) on cartilage cytokines and transcription factor NF-kappaB: a study on induced arthritis in rats.
Efficacy and Safety of Celecoxib Therapy in Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials.
Efficacy and Safety of COX-2 Inhibitors in the Clinical Management of Arthritis: Mini Review.
Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis.
Emerging options with coxib therapy.
Etoricoxib for arthritis and pain management.
Evaluation of cyclooxygenase 2 inhibitor use in patients admitted to a large teaching hospital.
Experimental arthritis inhibits the insulin-like growth factor-I axis and induces muscle wasting through cyclooxygenase-2 activation.
Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases.
Expression of cyclooxygenase isoforms in the rat spinal cord and their regulation during adjuvant-induced arthritis.
Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis.
Formoterol decreases muscle wasting as well as inflammation in the rat model of rheumatoid arthritis.
Formulary decision-making considerations: COX-2 inhibitors.
Future trends in the development of safer nonsteroidal anti-inflammatory drugs.
G-CSF Receptor Blockade Ameliorates Arthritic Pain and Disease.
Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs.
Genetics of arthritis severity: A genome-wide and species-wide dissection in HS mice.
Going against the flow: the impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis.
Granulocyte-macrophage colony-stimulating factor is a key mediator in inflammatory and arthritic pain.
Human chondrocyte culture models for studying cyclooxygenase expression and prostaglandin regulation of collagen gene expression.
Identification and Characterization of Novel Microsomal Prostaglandin E Synthase-1 Inhibitors for Analgesia.
In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.
In Vivo Brain Imaging, Biodistribution, and Radiation Dosimetry Estimation of [11C]Celecoxib, a COX-2 PET Ligand, in Nonhuman Primates.
In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis.
In vivo evaluation of [11C]TMI, a COX-2 selective PET tracer, in baboons.
Inhibition of delayed rectifier potassium channels and induction of arrhythmia: a novel effect of celecoxib and the mechanism underlying it.
Inhibition of farnesyltransferase prevents collagen-induced arthritis by down-regulation of inflammatory gene expression through suppression of p21(ras)-dependent NF-kappaB activation.
Inhibition of interleukin-1beta-induced cyclooxygenase 2 expression in human synovial fibroblasts by 15-deoxy-Delta12,14-prostaglandin J2 through a histone deacetylase-independent mechanism.
Inhibition of PGE2 production by nimesulide compared with diclofenac in the acutely inflamed joint of patients with arthritis.
Inhibitory effects of JTE-522, a novel prostaglandin H synthase-2 inhibitor, on adjuvant-induced arthritis and bone changes in rats.
Interaction between inhibitors of inducible nitric oxide synthase and cyclooxygenase in adjuvant-induced arthritis in female albino rats: an isobolographic study.
Interactions between oxicams and membrane bilayers: an explanation for their different COX selectivity.
Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2.
Madecassoside attenuates inflammatory response on collagen-induced arthritis in DBA/1 mice.
Managing arthritis pain amid evolving science on pain relievers.
Mechanisms of progressive renal disease: role of angiotensin II, cyclooxygenase products and nitric oxide.
Melanocortin-4 receptor agonist (RO27-3225) ameliorates soleus but not gastrocnemius atrophy in arthritic rats.
Micro-CT imaging analysis for the effect of celecoxib, a cyclooxygenase-2 inhibitor, on inflammatory bone destruction in adjuvant arthritis rats.
Microsomal prostaglandin E synthase-1 is a major terminal synthase that is selectively up-regulated during cyclooxygenase-2-dependent prostaglandin E2 production in the rat adjuvant-induced arthritis model.
Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
Mitigation of arthritis by high-dose administration of a COX-2 inhibitor in the collagen-induced arthritis model in the mouse.
Monocyte cyclooxygenase-2 activity: a new therapeutic target for atherosclerosis?
Motion--Cyclo-oxygenase-2 selective nonsteroidal anti-inflammatory drugs are as safe as placebo for the stomach: arguments against the motion.
mPGES-1 null mice are resistant to bleomycin-induced skin fibrosis.
Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis.
Natural products as a gold mine for arthritis treatment.
New COX-2 arthritis drug receives FDA approval.
Niosomal gel for site-specific sustained delivery of anti-arthritic drug: in vitro-in vivo evaluation.
Nitric oxide (NO)-releasing naproxen (HCT-3012 [(S)-6-methoxy-alpha-methyl-2-naphthaleneacetic Acid 4-(nitrooxy)butyl ester]) interactions with aspirin in gastric mucosa of arthritic rats reveal a role for aspirin-triggered lipoxin, prostaglandins, and NO in gastric protection.
Nitric oxide enhances cyclooxygenase activity in articular cartilage.
Nitric oxide synthase and cyclooxygenase interactions in cartilage and meniscus: relationships to joint physiology, arthritis, and tissue repair.
Non-steroidal anti-inflammatory drugs for acute gout.
Novel insights and therapeutical applications in the field of inhibitors of COX-2.
NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib.
NSAID-induced gastrointestinal and cardiovascular injury.
NSAIDs and COX-2 inhibitors: what can we learn from large outcomes trials? The gastroenterologist's perspective.
Obesity does not diminish the efficacy of IL-6 signalling blockade in mice with collagen-induced arthritis.
Paederia foetida Linn. inhibits adjuvant induced arthritis by suppression of PGE(2) and COX-2 expression via nuclear factor-?B.
Pathogenesis of NSAID-induced gastric damage: importance of cyclooxygenase inhibition and gastric hypermotility.
Pharmacokinetics of rofecoxib in children with sickle cell hemoglobinopathy.
Pharmacokinetics of Rofecoxib in Children With Sickle Cell Hemoglobinopathy.
Pharmacological characterization of a selective COX-2 inhibitor MF-tricyclic, [3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone], in multiple preclinical species.
Possible Protective Role of Chloramphenicol in TSST-1 and Coagulase-Positive Staphylococcus aureus-Induced Septic Arthritis with Altered Levels of Inflammatory Mediators.
PPAR gamma ligands inhibit nitrotyrosine formation and inflammatory mediator expressions in adjuvant-induced rheumatoid arthritis mice.
Predominance of cyclooxygenase 1 over cyclooxygenase 2 in the generation of proinflammatory prostaglandins in autoantibody-driven K/BxN serum-transfer arthritis.
Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects.
Prostacyclin antagonism reduces pain and inflammation in rodent models of hyperalgesia and chronic arthritis.
Prostanoid Receptor EP2 as a Therapeutic Target.
Prostanoids as friends, not foes: further evidence from the interference by cycloxygenase-inhibitory drugs when inducing tolerance to experimental arthritigens in rats.
Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
Relationship of clinical factors to the use of Cox-2 selective NSAIDs within an arthritis population in a large HMO.
Reliability and validity of a modified Brief Pain Inventory short form in patients with osteoarthritis.
Resolution of etodolac and antiinflammatory and prostaglandin synthetase inhibiting properties of the enantiomers.
Resolution of Inflammation in Murine Autoimmune Arthritis Is Disrupted by Cyclooxygenase-2 Inhibition and Restored by Prostaglandin E2-Mediated Lipoxin A4 Production.
Risk of cardiovascular events associated with selective COX-2 inhibitors.
Risk-benefit perspectives in COX-2 blockade.
Role of cyclooxygenases in angiogenesis.
Scientific validation of Anti-arthritic effect of Kashayams - a polyherbal formulation in collagen induced arthritic rats.
Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice?
Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link?
Selective cyclooxygenase-2 inhibitors for the treatment of arthritis.
Selective cyclooxygenase-2 inhibitors: heteroaryl modified 1,2-diarylimidazoles are potent, orally active antiinflammatory agents.
Selective Inhibition of COX-2 by a Standardized CO2 Extract of Humulus lupulus in vitro and its Activity in a Mouse Model of Zymosan-Induced Arthritis.
Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis.
Selective inhibition of cyclooxygenase-2 with antisense oligodeoxynucleotide restricts induction of rat adjuvant-induced arthritis.
Serum concentrations of cyclooxygenase-2 in patients with systemic sclerosis: association with lower frequency of pulmonary fibrosis.
Sex differences in inflammation and inflammatory pain in cyclooxygenase-deficient mice.
Specific COX-2 inhibitors in arthritis, oncology, and beyond: where is the science headed?
Specific cyclooxygenase-2 (COX-2) inhibitors.
Specific cyclooxygenase-2 inhibitors: what have we learned since they came into widespread clinical use?
Structural efficacy of NSAIDs, COX-2 inhibitor and glucocorticoid compared with TNF? blocker: a study in adjuvant-induced arthritis rats.
Summaries for patients. The cost-effectiveness of cyclooxygenase-2 inhibitors for treating chronic arthritis.
Synthesis and quantitative structure-activity relationships of diclofenac analogues.
Terpenes as possible drugs for the mitigation of arthritic symptoms - A systematic review.
The AP-1 Transcription Factor c-Jun Promotes Arthritis by Regulating Cyclooxygenase-2 and Arginase-1 Expression in Macrophages.
The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
The COX-2 controversy continues ...but NSAIDs are still in the lead. New studies shed light on risks associated with popular arthritis painkillers.
The double-edged sword of COX-2 selective NSAIDs.
The effects of Celecoxib on inflammation and synovial microcirculation in murine antigen-induced arthritis.
The effects of cyclooxygenase 2 inhibitors on cartilage erosion and bone loss in a model of Mycobacterium tuberculosis-induced monoarticular arthritis in the rat.
The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritis.
The impact of nonsteroidal anti-inflammatory drug-induced gastropathy.
The management of pain in arthritis and the use of cyclooxygenase-2 inhibitors: new paradigms and insights.
The melanocortin receptor type 3 agonist d-Trp(8)-?MSH decreases inflammation and muscle wasting in arthritic rats.
The role of COX-2 produced by cartilage in arthritis.
The role of macrophage migration inhibitory factor in the inflammatory immune response and rheumatoid arthritis.
The snake venom metalloproteinase BaP1 induces joint hypernociception through TNF-alpha and PGE2-dependent mechanisms.
The unmet anti-inflammatory needs in orthopedics.
The use of anti-COX2 siRNA coated onto PLGA nanoparticles loading dexamethasone in the treatment of rheumatoid arthritis.
The usefulness and the limitations of animal models in identifying targets for therapy in arthritis.
Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics.
Therapeutic effects of standardized Vitex negundo seeds extract on complete Freund's adjuvant induced arthritis in rats.
Therapeutic potential of COX-2 inhibitors in arthritis.
Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
Topically Applied Phospho-Sulindac Hydrogel is Efficacious and Safe in the Treatment of Experimental Arthritis in Rats.
Treatments for Inflammatory Arthritis: Potential But Unproven Role of Topical Copaiba.
Ulcerogenic influence of selective cyclooxygenase-2 inhibitors in the rat stomach with adjuvant-induced arthritis.
Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
Update on the management of pain in arthritis and the use of cyclooxygenase-2 inhibitors.
Ursolic acid rich Ocimum sanctum L leaf extract loaded nanostructured lipid carriers ameliorate adjuvant induced arthritis in rats by inhibition of COX-1, COX-2, TNF-? and IL-1: Pharmacological and docking studies.
Use of COX-2 specific inhibitors in operative and nonoperative management of patients with arthritis.
Utilization patterns of cyclooxygenase-2 inhibitors among patients with arthritis in a managed care setting.
Valdecoxib (Pharmacia).
Valdecoxib-induced toxic epidermal necrolysis in a patient allergic to sulfa drugs.
Vision of the future in arthritis care.
Visual disturbance associated with celecoxib.
What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
[Can COX-2 selective inhibitor prevent NSAIDs-related GI toxicity?].
[COX-2 inhibitors: a new treatment in rheumatic diseases]
[Cyclooxygenase-2 (Cox-2) selective inhibitors: socioeconomic and pharmaco-epidemiologic aspects]
[New studies of COX-inhibitors, yet issues remain]
[Novel synthetic method and analgesic activity of tepoxalin].
[Side effects of COX-2 selective inhibitors. Critic related with its administration in patients with rheumatoid arthritis and osteoarthritis]
Arthritis, Experimental
Anti-inflammatory activity of a novel selective cyclooxygenase-2 inhibitor, FR140423, on type II collagen-induced arthritis in Lewis rats.
Anti-inflammatory and analgesic activity of a novel inhibitor of microsomal prostaglandin E synthase-1 expression.
Anti-inflammatory effects of Clematis chinensis Osbeck extract(AR-6) may be associated with NF-?B, TNF-?, and COX-2 in collagen-induced arthritis in rat.
Anti-inflammatory pharmacology and mechanism of the orally active capsaicin analogs, NE-19550 and NE-28345.
Antiinflammatory 2,6-di-tert-butyl-4-(2-arylethenyl)phenols.
Antiinflammatory benzimidazole derivative with inhibitory effects on neutrophil function.
Celecoxib prevents juxta-articular osteopenia and growth plate destruction adjacent to inflamed joints in rats with collagen-induced arthritis.
Changes in prostaglandin E2 (PGE2) levels in paw exudate, stomach and kidney of arthritic rats: effects of flosulide.
Chrysin alleviates testicular dysfunction in adjuvant arthritic rats via suppression of inflammation and apoptosis: comparison with celecoxib.
Effect of celecoxib, a cyclooxygenase-2 inhibitor, on the pathophysiology of adjuvant arthritis in rat.
Effect of inhibitors of eicosanoid metabolism in murine collagen-induced arthritis.
Effects of pentoxifylline and nabumetone on the serum levels of IL-1beta and TNFalpha in rats with adjuvant arthritis.
Effects of the second-generation leukotriene B(4) receptor antagonist, LY293111Na, on leukocyte infiltration and collagen-induced arthritis in mice.
Inhibitory effects of the root extract of Litsea cubeba (Lour.) Pers. on adjuvant arthritis in rats.
Lactobacillus casei reduces the Inflammatory Joint Damage Associated with Collagen-Induced Arthritis (CIA) by Reducing the Pro-Inflammatory Cytokines : Lactobacillus casei: COX-2 inhibitor.
Micro-CT imaging analysis for the effect of celecoxib, a cyclooxygenase-2 inhibitor, on inflammatory bone destruction in adjuvant arthritis rats.
Mitigation of arthritis by high-dose administration of a COX-2 inhibitor in the collagen-induced arthritis model in the mouse.
Nociception and the differential expression of cyclooxygenase-1 (COX-1), the COX-1 variant retaining intron-1 (COX-1v), and COX-2 in mouse dorsal root ganglia (DRG).
Pharmacology of celecoxib in rat brain after kainate administration.
Relations between functional, inflammatory, and degenerative parameters during adjuvant arthritis in rats.
Role of cyclooxygenase-2, but not cyclooxygenase-1, on type II collagen-induced arthritis in DBA/1J mice.
Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis.
Stereoisomeric relationships among anti-inflammatory activity, inhibition of platelet aggregation, and inhibition of prostaglandin synthetase.
The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritis.
The influence of anti-rheumatic drugs on hepatic mRNA levels of acute-phase proteins in rats with adjuvant arthritis.
The usefulness and the limitations of animal models in identifying targets for therapy in arthritis.
Therapeutic effects of the total lignans from Vitex negundo seeds on collagen-induced arthritis in rats.
[Analgesic effects of ionotropic glutamate receptor antagonists MK-801 and NBQX on collagen-induced arthritis rats].
[Antiphlogistic effectiveness of combinations of inhibitors of phospholipase A2, cyclooxygenase and lipoxygenases of the arachidonic acid cascade]
[Simultaneous and sequential inhibition of the arachidonic acid cascade by inhibitors of phospholipase A2, cyclooxygenase and lipoxygenases in carrageenan edema and adjuvant arthritis in the rat]
Arthritis, Gouty
Clinical pharmacology of etoricoxib.
Frontline Science: Reprogramming COX-2, 5-LOX, and CYP4A-mediated arachidonic acid metabolism in macrophages by salidroside alleviates gouty arthritis.
Soft coral-derived lemnalol alleviates monosodium urate-induced gouty arthritis in rats by inhibiting leukocyte infiltration and iNOS, COX-2 and c-Fos protein expression.
Arthritis, Infectious
Cyclooxygenase 2 activity modulates the severity of murine Lyme arthritis.
Arthritis, Juvenile
A selective COX-2 inhibitor, meloxicam, as a treatment option in patients with juvenile idiopathic arthritis and gastrointestinal side effects from naproxen.
Oligohydramnios and transient neonatal anuria: a possible association with the maternal use of prostaglandin synthetase inhibitors.
Arthritis, Psoriatic
A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis.
Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases.
Nephrotoxicity of selective COX-2 inhibitors.
Single subject pharmacological-MRI (phMRI) study: modulation of brain activity of psoriatic arthritis pain by cyclooxygenase-2 inhibitor.
Arthritis, Reactive
Antiinflammatory effects of etoricoxib alone and combined with NSAIDs in LPS-induced reactive arthritis.
Association between reactive arthritis and antecedent infection with Shigella flexneri carrying a 2-Md plasmid and encoding an HLA-B27 mimetic epitope.
Characterization of the stable maintenance of the Shigella flexneri plasmid pHS-2.
Arthritis, Rheumatoid
(-)-Epiafzelechin: cyclooxygenase-1 inhibitor and anti-inflammatory agent from aerial parts of Celastrus orbiculatus.
4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522(1).
A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis.
A double-blind, three-week study to compare the efficacy and safety of meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis.
A glycoprotein from Porphyra yezoensis produces anti-inflammatory effects in liposaccharide-stimulated macrophages via the TLR4 signaling pathway.
A mechanistic approach to understanding conjugated linoleic acid's role in inflammation using murine models of rheumatoid arthritis.
A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273].
A novel celecoxib derivative potently induces apoptosis of human synovial fibroblasts.
A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.
A randomized, double-blind, parallel-group study comparing the analgesic effect of etoricoxib to placebo, naproxen sodium, and acetaminophen with codeine using the dental impaction pain model.
A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
A review of the clinical pharmacokinetics of meloxicam.
A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis.
A systematic review on the role of eicosanoid pathways in rheumatoid arthritis.
Adiponectin receptor 1 mediates the difference in adiponectin- induced prostaglandin E2 production in rheumatoid arthritis and osteoarthritis synovial fibroblasts.
Aldosterone glucuronidation inhibition as a potential mechanism for arterial dysfunction associated with chronic celecoxib and diclofenac use in patients with rheumatoid arthritis.
An economic approach to health care.
Anti-arthritogenic effect of Saponin-1 by alteration of Th1/Th2 cytokine paradigm in arthritic mice.
Anti-inflammatory and anti-arthritic effects of the ethanolic extract of Aralia continentalis Kitag. in IL-1?-stimulated human fibroblast-like synoviocytes and rodent models of polyarthritis and nociception.
Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
Anti-inflammatory effects of N-acylethanolamines in rheumatoid arthritis synovial cells are mediated by TRPV1 and TRPA1 in a COX-2 dependent manner.
Anti-inflammatory effects of sphingosine kinase modulation in inflammatory arthritis.
Apigenin, a nonmutagenic dietary flavonoid suppresses lupus by inhibiting autoantigen presentation for expansion of autoreactive Th1 and Th17 cells.
Aspirin, NSAIDs, and COX-2 inhibitors in cardiovascular disease: possible interactions and implications for treatment of rheumatoid arthritis.
Atherosclerotic cardiovascular disease in rheumatoid arthritis.
Bioequivalence study of two brands of meloxicam tablets in healthy human Pakistani male subjects.
Can active components of licorice, glycyrrhizin and glycyrrhetinic acid, lick rheumatoid arthritis?
Cardiovascular hazard of selective COX-2 inhibitors: myth or reality?
Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results.
Celecoxib in osteoarthritis and rheumatoid arthritis: new preparation. As disappointing as rofecoxib.
Celecoxib inhibits Na+ currents in rat dorsal root ganglion neurons.
Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin.
Celecoxib, a cyclooxygenase-2 inhibitor, improved upper gastrointestinal lesions in rheumatoid arthritis patients as assessed by endoscopic evaluation.
Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis.
Celecoxib, a selective cyclooxygenase-2 inhibitor, reduces level of a bone resorption marker in postmenopausal women with rheumatoid arthritis.
Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis.
Celecoxib: a novel treatment for lung cancer.
Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention.
Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain.
Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.
Channelling of patients taking NSAIDs or cyclooxygenase-2-specific inhibitors and its effect on interpretation of outcomes.
Clinical pharmacology of etoricoxib.
Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor.
Clinical pharmacology of selective COX-2 inhibitors.
Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.
Clinical use and pharmacological properties of selective COX-2 inhibitors.
Coexpression of microsomal prostaglandin E synthase with cyclooxygenase-2 in human rheumatoid synovial cells.
Comparative Study of Normal and Rheumatoid Arthritis Fibroblast-Like Synoviocytes Proliferation under Cyclic Mechanical Stretch: Role of Prostaglandin E(2).
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis.
Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis.
COX-1 and COX-2 tissue expression: implications and predictions.
COX-2 and colon cancer: Potential targets for chemoprevention.
COX-2 and colon cancer: potential targets for chemoprevention.
Cox-2 gene variants in migraine.
COX-2 inhibitors in rheumatoid arthritis.
COX-2 Inhibitors Modulate IL-12 Signaling Through JAK-STAT Pathway Leading to Th1 Response in Experimental Allergic Encephalomyelitis.
COX-2 inhibitors.
COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
COX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients.
COXIBs and non-selective NSAIDs in the gastroenterological setting: what should patients and physicians do?
Current considerations for the management of musculoskeletal pain in Asian countries: a special focus on cyclooxygenase-2 inhibitors and non-steroid anti-inflammation drugs.
Cyclic mechanical stretch downregulates IL-1β-induced COX-2 expression and PGE2 production in rheumatoid arthritis fibroblast-like synoviocytes.
Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9.
Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis.
Cyclooxygenase 2 activity modulates the severity of murine Lyme arthritis.
Cyclooxygenase 2-derived prostaglandin E2 production by corticotropin-releasing hormone contributes to the activated cAMP response element binding protein content in rheumatoid arthritis synovial tissue.
Cyclooxygenase inhibitors enhance the production of tissue inhibitor-1 of metalloproteinases (TIMP-1) and pro-matrix metalloproteinase 1 (proMMP-1) in human rheumatoid synovial fibroblasts.
Cyclooxygenase inhibitors--current status and future prospects.
Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids.
Cyclooxygenase-1 and -2 isoenzymes.
Cyclooxygenase-2 genotype and rheumatoid arthritis.
Cyclooxygenase-2 inhibitor celecoxib: a possible cause of gastropathy and hypoprothrombinemia.
Cyclooxygenase-2 polymorphisms and risk of rheumatoid arthritis in Koreans.
Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors.
Cysteinyl leukotriene receptor antagonism: a promising pharmacological strategy for lowering the severity of arthritis.
Defining COX-2 inhibitors.
Design and Synthesis of Novel Nonsteroidal Anti-Inflammatory Drugs and Carbonic Anhydrase Inhibitors Hybrids (NSAIDs-CAIs) for the Treatment of Rheumatoid Arthritis.
Development of an HPLC assay to study the effect of endogenous and exogenous substances on heat-induced aggregation of human serum albumin.
Development of Diagnostic Techniques for Early Rheumatoid Arthritis Using Positron Emission Tomography with [(11)C]PK11195 and [(11)C]Ketoprofen Tracers.
Differential expression of COX-2 in osteoarthritis and rheumatoid arthritis.
Diosgenin, a plant steroid, induces apoptosis in human rheumatoid arthritis synoviocytes with cyclooxygenase-2 overexpression.
Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human.
Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor.
DMARD aurothiomalate inhibits COX-2, MMP-3 and IL-6 expression in chondrocytes by increasing MKP-1 expression and decreasing p38 phosphorylation.
Do COX-2 inhibitors provide additional pain relief and anti-inflammatory effects in patients with rheumatoid arthritis who are on biological disease-modifying anti-rheumatic drugs and/or corticosteroids? Post-hoc analyses from a randomized clinical trial with etoricoxib.
Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.
Effect of the misoprostol-rebamipide combination on iron deficiency anemia in patients under long-term cyclooxygenase-2 selective inhibitor treatment for small bowel ulcers.
Effects of celecoxib on the expression of osteoprotegerin, energy metabolism and cell viability in cultured human osteoblastic cells.
Effects of cyclooxygenases inhibitors on vasoactive prostanoids and thrombin generation at the site of microvascular injury in healthy men.
Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite.
Effects of human cyclooxygenase-2 gene silencing on synovial cells of rheumatoid arthritis mediated by lentivirus.
Effects of tenidap on Ca(2+)- and protein kinase C-mediated protein phosphorylation, activation of the arachidonate-mobilizing phospholipase A2 and subsequent eicosanoid formation in macrophages.
Effects of valdecoxib in the treatment of chronic low back pain: results of a randomized, placebo-controlled trial.
Efficacy and Safety of the Selective Cyclooxygenase-2 Inhibitor Celecoxib in the Treatment of Rheumatoid Arthritis and Osteoarthritis in Japan.
Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen.
Efficacy and tolerability of naproxen/esomeprazole magnesium tablets compared with non-specific NSAIDs and COX-2 inhibitors: a systematic review and network analyses.
Efficacy of lumiracoxib in osteoarthritis: a review of nine studies.
Enhancement of PLGF production by 15-(S)-HETE via PI3K-Akt, NF-?B and COX-2 pathways in rheumatoid arthritis synovial fibroblast.
Epithelium-specific Ets transcription factor-1 acts as a negative regulator of cyclooxygenase-2 in human rheumatoid arthritis synovial fibroblasts.
Ethyl acetate fraction from Angelica sinensis inhibits IL-1?-induced rheumatoid synovial fibroblast proliferation and COX-2, PGE2, and MMPs production.
Ethyl acetate fraction from Cudrania tricuspidata inhibits IL-1?-induced rheumatoid synovial fibroblast proliferation and MMPs, COX-2 and PGE2 production.
Etodolac: An overview of a selective COX-2 inhibitor.
Etoricoxib versus naproxen in patients with rheumatoid arthritis: a prospective, randomized, comparator-controlled 121-week trial.
Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial.
Evening primrose oil and borage oil in rheumatologic conditions.
Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond.
Expectations from patients with rheumatoid arthritis regarding COX-2s: cutting to the heart of the matter.
Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases.
Expression of cyclooxygenase-1 and -2 in rheumatoid arthritis synovium.
Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis.
Fish oil supplementation increases the cyclooxygenase inhibitory activity of paracetamol in rheumatoid arthritis patients.
FK506 augments glucocorticoid-mediated cyclooxygenase-2 down-regulation in human rheumatoid synovial fibroblasts.
FK506 enhances triptolide-induced down-regulation of cyclooxygenase-2, inducible nitric oxide synthase as well as their products PGE2 and NO in TNF-alpha-stimulated synovial fibroblasts from rheumatoid arthritic patients.
Flurbiprofen in the symptomatic management of rheumatoid arthritis: a valuable alternative.
Formulation and evaluation of mouth dissolving tablets of the Etoricoxib.
Further assessment of the clinically effective dose range of etoricoxib: a randomized, double-blinded, placebo-controlled trial in rheumatoid arthritis.
Global safety of coxibs and NSAIDs.
Glucocorticoid-induced leucine zipper (GILZ) mediates glucocorticoid action and inhibits inflammatory cytokine-induced COX-2 expression.
How to mechanistically explain the CONDOR study data.
Improved solubilization of Celecoxib in U-type nonionic microemulsions and their structural transitions with progressive aqueous dilution.
In vitro characterization of chitosan gels for buccal delivery of celecoxib: influence of a penetration enhancer.
In vitro cytotoxic evaluation of some synthesized COX-2 inhibitor derivatives against a panel of human cancer cell lines.
In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis.
Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis.
Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors.
Induction of cyclooxygenase-1 in cultured synovial cells isolated from rheumatoid arthritis patients.
Influence of polymers on the bioavailability of microencapsulated celecoxib.
Inhibition of human rheumatoid arthritis synovial cell survival by hecogenin and tigogenin is associated with increased apoptosis, p38 mitogen-activated protein kinase activity and upregulation of cyclooxygenase-2.
Iridoid glycosides from the flowers of Gentiana macrophylla Pall. ameliorate collagen-induced arthritis in rats.
Isolation and structural characterization of the photolysis products of etoricoxib.
Kaempferol inhibits IL?1??induced proliferation of rheumatoid arthritis synovial fibroblasts and the production of COX?2, PGE2 and MMPs.
Low-dose aspirin in the primary prevention of rheumatoid arthritis: the Women's Health Study.
Lumiracoxib (Novartis).
Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: results of three dose-response studies.
Managing the adverse effects of nonsteroidal anti-inflammatory drugs.
MAP kinase subtypes and Akt regulate diosgenin-induced apoptosis of rheumatoid synovial cells in association with COX-2 expression and prostanoid production.
Matching by Propensity Score in Cohort Studies with Three Treatment Groups.
Mechanism of action of aspirin-like drugs.
Mechanism of action of celastrol against rheumatoid arthritis: A network pharmacology analysis.
Mechanism of action of paracetamol.
Mechanisms of action of paracetamol and related analgesics.
Melittin inhibits inflammatory target gene expression and mediator generation via interaction with IkappaB kinase.
Meloxicam in the management of post-operative pain: Narrative review.
Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis.
Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis.
Methotrexate as a preferential cyclooxygenase 2 inhibitor in whole blood of patients with rheumatoid arthritis.
Micro-CT imaging analysis for the effect of celecoxib, a cyclooxygenase-2 inhibitor, on inflammatory bone destruction in adjuvant arthritis rats.
Microsomal prostaglandin E synthase is regulated by proinflammatory cytokines and glucocorticoids in primary rheumatoid synovial cells.
Migratory pulmonary infiltrates in a patient with rheumatoid arthritis.
Molecular insights into the differences in anti-inflammatory activities of green tea catechins on IL-1? signaling in rheumatoid arthritis synovial fibroblasts.
Molecular targets of dietary polyphenols with anti-inflammatory properties.
Murine mPGES-1 3D structure elucidation and inhibitors binding mode predictions by homology modeling and site-directed mutagenesis.
NCX-4016 (NicOx SA).
Nimesulide improves the symptomatic and disease modifying effects of leflunomide in collagen induced arthritis.
Nitric oxide (NO)-releasing naproxen (HCT-3012 [(S)-6-methoxy-alpha-methyl-2-naphthaleneacetic Acid 4-(nitrooxy)butyl ester]) interactions with aspirin in gastric mucosa of arthritic rats reveal a role for aspirin-triggered lipoxin, prostaglandins, and NO in gastric protection.
Non steroidal anti-inflammatory and anti-allergy agents.
Non-steroidal anti-inflammatory agent inhibit the synthesis of IgM rheumatoid factor in vitro.
Novel acid-type cyclooxygenase-2 inhibitors: Design, synthesis, and structure-activity relationship for anti-inflammatory drug.
Novel therapeutic strategies.
Oral treatment with HE3286 ameliorates disease in rodent models of rheumatoid arthritis.
Osteoarthritis and rheumatoid arthritis: will new data clarify the risk:benefit ratio of cyclooxygenase-2 inhibitors?
Outcome of specific COX-2 inhibition in rheumatoid arthritis.
Overexpression of cyclooxygenase-2 induces cell cycle arrest. Evidence for a prostaglandin-independent mechanism.
Paeoniflorin ameliorates rheumatoid arthritis in rat models through oxidative stress, inflammation and cyclooxygenase 2.
Pain management in osteoarthritis: the role of COX-2 inhibitors.
Pain Relieving Effect of-NSAIDs-CAIs Hybrid Molecules: Systemic and Intra-Articular Treatments against Rheumatoid Arthritis.
Pattern of use and safety of non-steroidal anti-inflammatory drugs in rheumatoid arthritis patients. A prospective analysis from clinical practice.
Persistence with non-selective NSAIDs and celecoxib among patients with gastroesophageal reflux disease and osteoarthritis or rheumatoid arthritis.
Persisting eicosanoid pathways in rheumatic diseases.
Pharmacoeconomics of coxib therapy.
Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects.
Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood.
Pharmacophore generation and atom-based 3D-QSAR of novel 2-(4-methylsulfonylphenyl)pyrimidines as COX-2 inhibitors.
Possible background mechanisms of the effectiveness of cyclooxygenase-2 inhibitors in the treatment of rheumatoid arthritis.
PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines.
Preclinical Explorative Assessment of Celecoxib-Based Biocompatible Lipidic Nanocarriers for the Management of CFA-Induced Rheumatoid Arthritis in Wistar Rats.
Preferential inhibition of cyclooxygenase-2 by meloxicam in human rheumatoid synoviocytes.
Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects.
Preparation, characterization, and evaluation of celecoxib eutectic mixtures with adipic acid/saccharin for improvement of wettability and dissolution rate.
Prescriptions for cyclooxygenase-2 inhibitors and other nonsteroidal anti-inflammatory agents in a medicaid managed care population: African Americans versus Caucasians.
Prostaglandin E2 synthesizing enzymes in rheumatoid arthritis B cells and the effects of B cell depleting therapy on enzyme expression.
Prostaglandin synthetase activity from human rheumatoid synovial microsomes. Effect of 'aspirin-like' drug therapy.
Protective effect of taraxasterol against rheumatoid arthritis by the modulation of inflammatory responses in mice.
Quercetin inhibits IL-1?-induced proliferation and production of MMPs, COX-2, and PGE2 by rheumatoid synovial fibroblast.
Rationale for testing the cardiovascular risk for patients with COX-2 inhibitors on the basis of biomarker NT-proBNP.
Regulation of natural killer cell activity by macrophages in the rheumatoid joint and peripheral blood.
Relationship of clinical factors to the use of Cox-2 selective NSAIDs within an arthritis population in a large HMO.
Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis.
Resveratrol inhibits BK-induced COX-2 transcription by suppressing acetylation of AP-1 and NF-?B in human rheumatoid arthritis synovial fibroblasts.
Risk assessment of NSAID-induced gastrointestinal toxicity in ambulatory care patients.
Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
Role and regulation of cyclooxygenase-2 during inflammation.
Role of cyclooxygenase-1 and -2 in health and disease.
Role of cyclooxygenases in angiogenesis.
Selective COX-2 inhibitor, NS-398, inhibits the replicative senescence of cultured dermal fibroblasts.
Selective cyclooxygenase-2 inhibitors for the treatment of arthritis.
Selective inhibition of cyclooxygenase 2-generated prostaglandin E2 synthesis in rheumatoid arthritis synoviocytes by taurine chloramine.
Selective inhibition of cyclooxygenase-2 with antisense oligodeoxynucleotide restricts induction of rat adjuvant-induced arthritis.
Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2.
Selenium Nanoparticles Dispersed in Phytochemical Exert Anti-Inflammatory Activity by Modulating Catalase, GPx1, and COX-2 Gene Expression in a Rheumatoid Arthritis Rat Model.
Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention.
Simultaneous profiling of eicosanoid metabolome in plasma by UPLC-MS/MS method: Application to identify potential makers for rheumatoid arthritis.
Single dose oral celecoxib for postoperative pain.
Stimulatory role of lysophosphatidic acid in cyclooxygenase-2 induction by synovial fluid